var title_f24_60_25536="Paraneoplastic pemphigus DIF";
var content_f24_60_25536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Paraneoplastic pemphigus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intercellular deposition of IgG is evident on direct immunofluorescence microscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25536=[""].join("\n");
var outline_f24_60_25536=null;
var title_f24_60_25537="Diphenhydramine: Patient drug information";
var content_f24_60_25537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diphenhydramine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?11/57/12182?source=see_link\">",
"       Diphenhydramine (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?4/10/4260?source=see_link\">",
"       Diphenhydramine (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11632 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25537=[""].join("\n");
var outline_f24_60_25537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/57/12182?source=related_link\">",
"      Diphenhydramine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/10/4260?source=related_link\">",
"      Diphenhydramine (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_60_25538="Widow spider B";
var content_f24_60_25538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Redback spider 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Julian White, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25538=[""].join("\n");
var outline_f24_60_25538=null;
var title_f24_60_25539="Echo parasternal long axis post MI MR";
var content_f24_60_25539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/52748/palaxmrp_conv.mp4?title=Echo+parasternal+long+axis+post+MI+MR\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram parasternal long axis post MI mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 244px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal long axis view shows an immobile posterior mitral valve leaflet, a result of a previous inferior wall myocardial infarction and papillary muscle dysfunction. The left atrium is enlarged, suggesting the presence of mitral regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25539=[""].join("\n");
var outline_f24_60_25539=null;
var title_f24_60_25540="Meningioma: Clinical presentation and diagnosis";
var content_f24_60_25540=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Meningioma: Clinical presentation and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25540/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25540/contributors\">",
"     John K Park, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25540/contributors\">",
"     Peter McLaren Black, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25540/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25540/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25540/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25540/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25540/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/60/25540/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 29, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningiomas are among the most frequent primary brain tumors (",
"    <a class=\"graphic graphic_table graphicRef81566 \" href=\"UTD.htm?6/44/6862\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72275 \" href=\"UTD.htm?28/44/29391\">",
"     figure 1",
"    </a>",
"    ). Although most meningiomas are benign, their location in the central nervous system can cause serious morbidity or mortality. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/2997?source=see_link\">",
"     \"Incidence of primary brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation and diagnosis of meningiomas will be reviewed here. Other topics on meningioma include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningioma: Epidemiology and risk factors (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=see_link\">",
"       \"Meningioma: Epidemiology, risk factors, and pathology\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment of WHO grade I (benign) meningiomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=see_link\">",
"       \"Treatment of benign (WHO grade I) meningioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Treatment of WHO grade II and III meningiomas (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42389?source=see_link\">",
"       \"Atypical and malignant meningiomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Systemic therapy for recurrent meningioma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4133?source=see_link\">",
"       \"Systemic treatment of recurrent meningioma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningiomas can arise anywhere from the dura, most commonly within the skull and at sites of dural reflection (falx cerebri, tentorium cerebelli, venous sinuses) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/1\">",
"     1",
"    </a>",
"    ]. Other less common sites include the optic nerve sheath and choroid plexus; approximately 10 percent arise in the spine. Very rarely, meningiomas can arise at extradural sites [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms from a meningioma are determined by the location of the mass and by the time course over which the tumor develops. Meningiomas frequently are extremely slow growing and often are asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical presentation and diagnosis of brain tumors\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Asymptomatic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many meningiomas are asymptomatic or minimally symptomatic, and are discovered incidentally on a neuroimaging study or at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Follow-up studies on patients with asymptomatic meningiomas suggest that most such tumors either remain the same size or grow slowly over prolonged periods [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of meningioma in an asymptomatic population was illustrated by a study of 2000 individuals who underwent MRI as part of a research study of aging [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/3\">",
"     3",
"    </a>",
"    ]. Meningiomas were identified in 18 (0.9 percent), and the incidence increased with age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are present preoperatively in 25 to 40 percent of patients who are diagnosed with an intracranial meningioma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In one contemporary series, the median duration of seizures before diagnosis was one month, which is considerably shorter than that observed prior to the availability of CT and MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/8\">",
"     8",
"    </a>",
"    ]. In one retrospective review, preoperative epilepsy was more common in patients with supratentorial meningiomas, tumors located at the convexity, and tumors associated with severe peritumoral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Focal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic focal deficits are caused by tumors in specific locations. Examples of such lesions include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Visual changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual changes, which are often unrecognized, are common in meningioma. In one series of 80 patients, approximately one-third had symptoms of visual loss, field defects,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diplopia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual field defects may be caused by parasellar meningiomas.",
"     </li>",
"     <li>",
"      Optic atrophy in one eye and papilledema in the other, the so-called Foster-Kennedy syndrome, can be produced by parasellar or subfrontal meningiomas.",
"     </li>",
"     <li>",
"      Progressive unilateral visual loss, which may be mistaken for optic neuritis, can be caused by optic nerve sheath meningiomas.",
"     </li>",
"     <li>",
"      Mild weakness of extraocular movements has been associated with cavernous sinus meningiomas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cerebellopontine angle meningioma can produce sensorineural hearing loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Mental status changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental status changes with neglect and inattention may result from surprisingly large subfrontal or sphenoid ridge meningiomas. Similar or even larger sized tentorial notch and intraventricular meningiomas are at times asymptomatic and diagnosed incidentally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Extremity weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningiomas at different sites can produce characteristic patterns of extremity weakness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A parasagittal meningioma growing on the falx and compressing the motor strip can lead to bilateral leg weakness in the absence of a spinal cord lesion.",
"     </li>",
"     <li>",
"      Foramen magnum meningiomas may produce a subtly progressive sequence of ipsilateral arm, then leg weakness, which is followed by contralateral leg and arm weakness that may be misdiagnosed as multiple sclerosis.",
"     </li>",
"     <li>",
"      Spinal meningiomas frequently present with progressive leg weakness and numbness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Obstructive hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large tumors in the posterior cranial fossa can cause obstructive hydrocephalus, and present with papilledema and classic early morning headache.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Spontaneous hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although meningiomas are highly vascularized tumors, symptomatic spontaneous hemorrhage as the initial manifestation of a previously undiagnosed meningioma is extremely rare [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of meningioma and classification as benign, atypical, or malignant (WHO grades I, II, and III, respectively) requires histologic confirmation. However, imaging studies often provide a tentative diagnosis and may be sufficient for treatment when obtaining tissue for pathologic confirmation entails too high a risk of causing further neurologic deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of an intracranial tumor may be suggested by the clinical presentation and is confirmed with magnetic resonance imaging (MRI) or computed tomography (CT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI is the preferred imaging modality because it can show the dural origin of the tumor in most cases. The typical meningioma is isointense or hypointense to gray matter on T1 and isointense or hyperintense on proton density and T2 weighted images; there is strong homogeneous enhancement with gadolinium (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59777 \" href=\"UTD.htm?21/38/22117\">",
"     image 1",
"    </a>",
"    ). Most meningiomas show a characteristic marginal dural thickening that tapers peripherally (the \"tail\" sign) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65731 \" href=\"UTD.htm?36/24/37248\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    On CT, the typical meningioma is a well-defined extra-axial mass that displaces the normal brain. They are smooth in contour, adjacent to dural structures, and sometimes calcified or multilobulated. Isointensity with normal surrounding brain may make diagnosis difficult on a non-contrasted scan, but intravenous contrast administration results in uniformly bright enhancement. Secondary involvement of adjacent bone (reactive sclerosis, invasion, erosion) is uncommon with convexity meningiomas, but occurs in up to one-half of skull base tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the development of MRI and CT, angiography was used to suggest the diagnosis of meningioma by demonstrating arterial supply from meningeal vessels and the delayed vascular blush that is characteristic of these lesions. The use of angiography now is limited to tumor embolization as a component of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of benign (WHO grade I) meningioma\", section on 'Extent of resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although results from positron emission tomography (PET) may predict the aggressiveness of a meningioma and the potential for recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/13\">",
"     13",
"    </a>",
"    ], PET is not routinely used since maximal surgical resection is the goal for all grades of meningioma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other disease processes can involve the dura or subdural space, resulting in an appearance on MRI or CT that may suggest meningioma. These include lymphoma, metastatic carcinoma, inflammatory lesions such as sarcoidosis and Wegener's granulomatosis, and infections such as tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25540/abstract/1,14,15\">",
"     1,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444766081\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningiomas can arise anywhere from the dura, most commonly within the skull. Approximately 10 percent arise in the spinal cord. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many meningiomas are slow growing and discovered incidentally on a neuroimaging study. These may be asymptomatic or minimally symptomatic. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Asymptomatic tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms can vary widely, depending upon by the location of the mass. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Focal findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial diagnosis of a brain tumor is based upon neuroimaging results, and the specific diagnosis and classification is confirmed based upon histopathology. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/1\">",
"      Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet 2004; 363:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/2\">",
"      Mattox A, Hughes B, Oleson J, et al. Treatment recommendations for primary extradural meningiomas. Cancer 2011; 117:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/3\">",
"      Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/4\">",
"      Annegers JF, Schoenberg BS, Okazaki H, Kurland LT. Epidemiologic study of primary intracranial neoplasms. Arch Neurol 1981; 38:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/5\">",
"      Nakasu S, Hirano A, Shimura T, Llena JF. Incidental meningiomas in autopsy study. Surg Neurol 1987; 27:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/6\">",
"      Niiro M, Yatsushiro K, Nakamura K, et al. Natural history of elderly patients with asymptomatic meningiomas. J Neurol Neurosurg Psychiatry 2000; 68:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/7\">",
"      Go RS, Taylor BV, Kimmel DW. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology 1998; 51:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/8\">",
"      Chozick BS, Reinert SE, Greenblatt SH. Incidence of seizures after surgery for supratentorial meningiomas: a modern analysis. J Neurosurg 1996; 84:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/9\">",
"      Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res 2000; 38:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/10\">",
"      Anderson D, Khalil M. Meningioma and the ophthalmologist. A review of 80 cases. Ophthalmology 1981; 88:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/11\">",
"      Bosnjak R, Derham C, Popovi M, Ravnik J. Spontaneous intracranial meningioma bleeding: clinicopathological features and outcome. J Neurosurg 2005; 103:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/12\">",
"      Pieper DR, Al-Mefty O, Hanada Y, Buechner D. Hyperostosis associated with meningioma of the cranial base: secondary changes or tumor invasion. Neurosurgery 1999; 44:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/13\">",
"      Weber DC, Lovblad KO, Rogers L. New pathology classification, imagery techniques and prospective trials for meningiomas: the future looks bright. Curr Opin Neurol 2010; 23:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/14\">",
"      Johnson MD, Powell SZ, Boyer PJ, et al. Dural lesions mimicking meningiomas. Hum Pathol 2002; 33:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25540/abstract/15\">",
"      Tu PH, Giannini C, Judkins AR, et al. Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol 2005; 23:5718.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5220 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25540=[""].join("\n");
var outline_f24_60_25540=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H444766081\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Asymptomatic tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Focal findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Visual changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Mental status changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Extremity weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Obstructive hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Spontaneous hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444766081\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5220|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/38/22117\" title=\"diagnostic image 1\">",
"      Intracranial meningioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/24/37248\" title=\"diagnostic image 2\">",
"      Radiographic features of meningioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5220|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/44/29391\" title=\"figure 1\">",
"      Incidence rates of primary brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5220|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/44/6862\" title=\"table 1\">",
"      CBTRUS incidence of primary CNS tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42389?source=related_link\">",
"      Atypical and malignant meningiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/2997?source=related_link\">",
"      Incidence of primary brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/54/20328?source=related_link\">",
"      Meningioma: Epidemiology, risk factors, and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4133?source=related_link\">",
"      Systemic treatment of recurrent meningioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44616?source=related_link\">",
"      Treatment of benign (WHO grade I) meningioma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_60_25541="Desirudin: Drug information";
var content_f24_60_25541=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Desirudin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/0/26628?source=see_link\">",
"    see \"Desirudin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10011084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9590966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Iprivask&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9591045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticoagulant, Thrombin Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10011149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      DVT prophylaxis:",
"     </b>",
"     SubQ: 15 mg every 12 hours; initial dose may be given up to 5-15 minutes prior to surgery (after induction of regional anesthesia, if used); has been administered for up to 12 days (average: 9-12 days) in clinical trials",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10011150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10011151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;31-60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ): 5 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;31 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ): 1.7 mg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10011163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iprivask&reg;: 15 mg [supplied with prefilled diluent syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10011085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10011153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do",
"     <b>",
"      not",
"     </b>",
"     administer I.M.; for SubQ administration only. Administration should be alternated between the left and right anterolateral and left and right posterolateral thigh or abdominal wall. Insert needle into a skin fold held between the thumb and forefinger; the skin fold should be held throughout the injection. Do not rub injection site. Do not mix with other injections or infusions. Administer according to recommended regimen.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F10011134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix or administer with other injections, solvents, or infusions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9591047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis of deep vein thrombosis (DVT) in patients undergoing surgery for hip replacement",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9590943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10011093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all anticoagulants, bleeding is the major adverse effect. Hemorrhage may occur at any site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Hematoma (6%), hemorrhage (major, &lt;1% to 3%; may include cases of intracranial, retroperitoneal, intraocular, intraspinal, or prosthetic joint hemorrhage), anemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site mass (4%), deep thrombophlebitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Wound secretion (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Allergic reactions, anaphylactoid reaction, anaphylaxis, cerebrovascular disorder, dizziness, epistaxis, fever, healing impaired, hematemesis, hematuria, hemoglobin decreased, hemorrhage (fatal), hypotension, leg edema, leg pain, thrombosis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10011089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to natural or recombinant hirudins; active bleeding and/or irreversible coagulation disorders",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10011090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Anaphylaxis/hypersensitivity reactions: Allergic and hypersensitivity reactions, including anaphylaxis and fatal anaphylactoid reactions have been reported with other hirudin derivatives. Exercise caution when re-exposing patients (anaphylaxis has been reported).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; severe uncontrolled hypertension; history of hemorrhagic stroke; use shortly after brain, spinal, or ophthalmology surgery; patients treated concomitantly with platelet inhibitors; recent GI bleeding; thrombocytopenia or platelet defects; renal impairment; hepatic impairment; hypertensive or diabetic retinopathy; or in patients undergoing invasive procedures. Do not administer with other agents that increase the risk of hemorrhage unless coadministration cannot be avoided. Discontinue if bleeding occurs. Contraindicated with active bleeding and/or irreversible coagulation disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	 Renal impairment: Use with caution in patients with moderate-to-severe renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ); dosage reduction is necessary; monitor aPTT and renal function daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; elimination half-life prolonged in patients &gt;75 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do",
"     <b>",
"      not",
"     </b>",
"     administer intramuscularly (I.M.). Do not use interchangeably (unit-for-unit) with other hirudins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuraxial anesthesia:",
"     <b>",
"      [U.S. Boxed Warning]: Patients with recent or anticipated neuraxial anesthesia (epidural or spinal anesthesia) are at risk of epidural or spinal hematoma and subsequent paralysis.",
"     </b>",
"     Consider risk versus benefit prior to neuraxial anesthesia; risk is increased by concomitant agents which may alter hemostasis, as well as traumatic or repeated epidural or spinal puncture. Patient should be observed closely for bleeding and signs and symptoms of neurological impairment if therapy is administered during or immediately following diagnostic lumbar puncture, epidural anesthesia, or spinal anesthesia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10011125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10011129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, coleus, cordyceps, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American/Panax/Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, sweet clover, turmeric, white willow (all possess anticoagulant or antiplatelet activity and as such, may enhance the anticoagulant effects of desirudin).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10011086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10011087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in some animal reproduction studies. Data are insufficient to evaluate the safety of thrombin inhibitors during pregnancy (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10011088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13940949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the low enteral absorption of desirudin, it is unlikely to cause significant adverse events in a nursing infant, if it is present in breast milk. Use of desirudin may be continued in breast-feeding women (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Iprivask Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (1): $180.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10011156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor aPTT, serum creatinine/creatinine clearance, CBC; stool occult blood tests.  Serum creatinine and aPTT should be monitored daily in patients with moderate-to-severe renal insufficiency. Interrupt therapy if aPTT exceeds 2 times normal; resume at a reduced dose when aPTT is &lt;2 times control.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Revasc (AT, CZ, EE, FR, GB, GR, HN, IE, IT, MT, NL, NZ, PL, PT, RU, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10011135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Desirudin is a direct, highly selective thrombin inhibitor. Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation, activation of coagulation factors V, VII, and XIII, and thrombin-induced platelet aggregation resulting in a dose-dependent prolongation of the activated partial thromboplastin time (aPTT).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10011137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Subcutaneous: Complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 0.25 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~2 hours; Prolonged with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;31 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Up to 12 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (40% to 50% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e691-736.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25541/abstract-text/22315276/pubmed\" id=\"22315276\" target=\"_blank\">",
"        22315276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eriksson BI, Wille-Jorgensen P, Kalebo P, et al, &ldquo;A Comparison of Recombinant Hirudin With a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications After Total Hip Replacement,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(19):1329-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25541/abstract-text/9358126/pubmed\" id=\"9358126\" target=\"_blank\">",
"        9358126",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eriksson BI, Ekman S, Kalebo P, et al, &ldquo;Prevention of Deep-Vein Thrombosis After Total Hip Replacement: Direct Thrombin Inhibition With Recombinant Hirudin, CGP 39393,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1996, 347(9002):635-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25541/abstract-text/8596376/pubmed\" id=\"8596376\" target=\"_blank\">",
"        8596376",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eriksson BI, Ekman S, Lindbratt S, et al, &ldquo;Prevention of Thromboembolism With Use of Recombinant Hirudin. Results of a Double-blind, Multicenter Trial Comparing the Efficacy of Desirudin (Revasc) with that of Unfractionated Heparin in patients Having a Total Hip Replacement,&rdquo;",
"      <i>",
"       J Bone Joint Surg Am",
"      </i>",
"      , 1997, 79(3):326:33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25541/abstract-text/9070519/pubmed\" id=\"9070519\" target=\"_blank\">",
"        9070519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25541/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lefevre G, Duval M, Gauron S, et al, &ldquo;Effect Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Desirudin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1997, 62(1):50-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25541/abstract-text/9246019/pubmed\" id=\"9246019\" target=\"_blank\">",
"        9246019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8899 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25541=[""].join("\n");
var outline_f24_60_25541=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011084\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9590966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9591045\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011149\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011150\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011151\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796021\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011163\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011085\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011153\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011134\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9591047\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9590943\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011093\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011089\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011090\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299136\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011125\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011129\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011086\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011087\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011088\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13940949\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322761\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011156\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992815\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011135\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011137\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8899|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/0/26628?source=related_link\">",
"      Desirudin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_60_25542="Milrinone: Pediatric drug information";
var content_f24_60_25542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Milrinone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"    see \"Milrinone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/22/20835?source=see_link\">",
"    see \"Milrinone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F196740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Milrinone Lactate Injection;",
"     </li>",
"     <li>",
"      Primacor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phosphodiesterase Enzyme Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.: A limited number of studies have used different dosing schemes; optimal dose not established; further studies needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodynamic support: Full-term neonates: Loading dose: 50-75 mcg/kg administered over 15 minutes followed by a continuous infusion of 0.5 mcg/kg/minute; titrate to effect; range: 0.25-0.75 mcg/kg/minute has been used by several centers. One report used a loading dose of 50 mcg/kg administered over 15 minutes, followed by a continuous infusion of 0.5 mcg/kg/minute for 30 minutes in 10 neonates (3-27 days old, median age: 5 days) with low cardiac output after cardiac surgery; results showed improved hemodynamic parameters and milrinone was well tolerated (Chang, 1995)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of postoperative low cardiac output syndrome (CHD corrective surgery): Full-term neonates: Loading dose: 75 mcg/kg administered over 60 minutes followed by a continuous I.V. infusion of 0.75 mcg/kg/minute for 35 hours was used in a randomized, placebo-controlled trial of 227 patients (age: 2 days-6.9 years, median: 3 months) and showed 64% relative risk reduction for development of low cardiac output syndrome compared to placebo; a lower milrinone dose used in the study did not show a statistically significant relative risk reduction compared to placebo for the same endpoint  (Hoffman, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"      see \"Milrinone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: I.V.: A limited number of studies have used different dosing schemes. Two pharmacokinetic studies propose per kg doses for pediatric patients with septic shock that are greater than those recommended for adults (Lindsay, 1998) and in infants and children after cardiac surgery (Ramamoorthy, 1998). Further pharmacodynamic studies are needed to define pediatric milrinone guidelines. Several centers are using the following guidelines:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: 50 mcg/kg administered over 15 minutes followed by a continuous infusion of 0.5 mcg/kg/minute; range: 0.25-0.75 mcg/kg/minute; titrate dose to effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PALS Guidelines, 2010: I.V., I.O.: Loading dose: 50 mcg/kg administered over 10-60 minutes followed by a continuous infusion of 0.25-0.75 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: I.V.: Loading dose: 50 mcg/kg slow I.V. over 10 minutes, followed by a continuous infusion of 0.5 mcg/kg/minute; range: 0.375-0.75 mcg/kg/minute; titrate dose to effect; maximum daily dose: 1.13 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment",
"     </b>",
"     : Adult: Continuous I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer recommended adjustment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.43 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.38 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.33 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.28 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.23 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     5 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 0.2 mcg/kg/minute",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Alternative Dosing Adjustments in Patients with Renal Impairment",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Cl",
"         <sub>",
"          cr",
"         </sub>",
"         (mL/min)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Starting dose (mcg/kg/min)",
"         </b>",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          0.375",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          0.5",
"         </b>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          0.75",
"         </b>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"4\">",
"        <p style=\"text-indent:0em;text-align:left;\">",
"         <sup>",
"          1",
"         </sup>",
"         Based on expert opinion",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.375",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.125",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.375",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.0625",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.125",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Consider alternative therapy",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.0625",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.125",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Consider alternative therapy",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.0625",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Consider alternative therapy",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F196720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 200 mcg/mL (100 mL, 200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1 mg/mL (10 mL, 20 mL, 50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 1 mg/mL (10 mL, 20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F196706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Loading dose: Administer slow I.V. push over 15 minutes for pediatric patients and over 10 minutes in adults; loading dose may be given as undiluted solution, but may dilute to 10-20 mL (in adults) for ease of administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous I.V. infusion: Dilute with",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, or D",
"     <sub>",
"      5",
"     </sub>",
"     W and administer via infusion pump or syringe pump; usual concentration: &le;200 mcg/mL; 250 mcg/mL in NS has been used (Barton, 1996).",
"     <b>",
"      Note:",
"     </b>",
"     Some pediatric centers use a concentration of 500 mcg/mL but only if infused via a central line.",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     200",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F196776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amikacin, amiodarone, ampicillin, argatroban, atracurium, bivalirudin, bumetanide, calcium chloride, calcium gluconate, caspofungin, cefazolin, cefepime, cefotaxime, ceftazidime, cefuroxime, cimetidine, ciprofloxacin, clindamycin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, diltiazem, dobutamine, dopamine, doripenem, epinephrine, fenoldopam, fentanyl, gentamicin, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, insulin (regular), isoproterenol, labetalol, lorazepam, magnesium sulfate, meropenem, methylprednisolone sodium succinate, metoprolol, metronidazole, micafungin, midazolam, morphine, nesiritide, nicardipine, nitroglycerin, nitroprusside, norepinephrine, oxacillin, pancuronium, piperacillin, piperacillin/tazobactam, potassium chloride, propofol, propranolol, quinidine gluconate, ranitidine, rocuronium, sodium bicarbonate, telavancin, theophylline, thiopental, ticarcillin/clavulanate, tobramycin, torsemide, vancomycin, vasopressin, vecuronium, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide, imipenem/cilastin, procainamide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, calcium chloride, digoxin, epinephrine, lidocaine, morphine, propranolol, sodium bicarbonate, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Furosemide.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Storage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Injection: Store at controlled room temperature 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); avoid freezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premixed infusion: Store at room temperature at 25&deg;C (77&deg;F); brief exposure up to 40&deg;C (104&deg;F) will not adversely affect drug; minimize exposure to heat; avoid excessive heat; protect from freezing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of acute decompensated heart failure (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F196778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Primacor&reg; may be confused with Primaxin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F196775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, hypotension, supraventricular arrhythmia, ventricular arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, atrial fibrillation, bronchospasm, hypokalemia, injection site reaction, liver function abnormalities, MI, rash, thrombocytopenia, torsade de pointes, tremor, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to milrinone, any component, or inamrinone (amrinone)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in patients with severe obstructive aortic or pulmonic valvular disease; use in patients with hypertrophic subaortic stenosis may increase outflow tract obstruction. Use with caution in patients with a history of ventricular arrhythmias, atrial fibrillation, or atrial flutter. Use with caution and modify dosage in patients with impaired renal function. Hypotension may occur; monitor blood pressure and heart rate; infusion may require reduction in rate or temporary discontinuation if hypotension occurs; hypotension may be prolonged, especially in patients with renal dysfunction. Infusion site reactions may occur; monitor infusion site carefully. Milrinone is not recommended for use in patients with acute MI.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Longer treatment of heart failure (&gt;48 hours) has not been shown to be safe and effective (there are no controlled trials using milrinone infusions for &gt;48 hours); long-term oral use for heart failure was associated with no improvement in symptoms, increased risk of hospitalization, and increased risk of sudden death; monitor ECG continuously to promptly detect and manage ventricular arrhythmias. Long-term, regularly scheduled intermittent infusions are strongly discouraged (ACC/AHA 2005 Guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F196716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13334385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies; however, increased resorption was reported in some studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, cardiac output, CI, SVR, PVR, CVP, ECG, CBC, platelet count, serum electrolytes (especially potassium and magnesium), liver enzymes, renal function; clinical signs and symptoms of CHF; monitor infusion site carefully (avoid extravasation)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits phosphodiesterase III (PDE III), the major PDE in cardiac and vascular tissues. Inhibition of PDE III increases cyclic adenosine monophosphate (cAMP) which potentiates the delivery of calcium to myocardial contractile systems and results in a positive inotropic effect. Inhibition of PDE III in vascular tissue results in relaxation of vascular muscle and vasodilatation.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action (improved hemodynamic function): Within 5-15 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     beta:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants (after cardiac surgery): 0.9 &plusmn; 0.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children (after cardiac surgery): 0.7 &plusmn; 0.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     After cardiac surgery: 0.3 &plusmn; 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CHF (with single injection): 0.38 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CHF (with infusion): 0.45 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants (after cardiac surgery): 3.15 &plusmn; 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children (after cardiac surgery): 1.86 &plusmn; 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     After cardiac surgery: 1.69 &plusmn; 0.18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CHF: 2.3-2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal impairment: Prolonged half-life",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted in the urine as unchanged drug (83%) and glucuronide metabolite (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants (after cardiac surgery): 3.8 &plusmn; 1 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children (after cardiac surgery): 5.9 &plusmn; 2 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children (with septic shock): 10.6 &plusmn; 5.3 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     After cardiac surgery: 2 &plusmn; 0.7 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CHF: 2.2-2.3 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Renal impairment: Decreased clearance",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing schemes and proposed dosing based on pharmacokinetic data:",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Infants and children with septic shock:",
"     </b>",
"     Twelve patients (9 months to 15 years of age) were administered a loading dose of 50 mcg/kg, followed by a continuous infusion of 0.5 mcg/kg/minute. At 1 hour after the loading dose, if patients did not respond (defined as a &ge;20% increase in CI or an improvement in peripheral perfusion), an additional loading dose of 25 mcg/kg was given and the infusion rate was increased to 0.75 mcg/kg/minute. Nine of 12 patients required the additional loading dose and increased rate of infusion (Barton, 1996). A subsequent pharmacokinetic analysis of these patients recommended larger loading doses of 75 mcg/kg and infusion rates of 0.75-1 mcg/kg/minute. However, these doses were based on a one-compartment pharmacokinetic model and are higher then the mean infusion rate of 0.69 mcg/kg/minute used in the study (Lindsay, 1998). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Infants and Children after open heart surgery:",
"     </b>",
"     A prospective, open-label trial compared a lower dose of milrinone (Group A) to a higher dose (Group B). Group A: Eleven patients received a loading dose of 25 mcg/kg given over 5 minutes followed by an infusion of 0.25 mcg/kg/minute; 30 minutes later, a second 25 mcg/kg loading dose was given and the infusion was increased to 0.5 mcg/kg/minute. Group B: 8 patients received a loading dose of 50 mcg/kg given over 10 minutes followed by an infusion of 0.5 mcg/kg/minute; 30 minutes later, a second loading dose of 25 mcg/kg was given and the infusion was increased to 0.75 mcg/kg/minute. Patients in both groups received a third loading dose of 25 mcg/kg if needed. A two-compartment model and NONMEM pharmacokinetic analyses were performed. Based on the NONMEM analysis, the authors propose the following doses: Infants: Loading dose: 104 mcg/kg and continuous infusion of 0.49 mcg/kg/minute; children: loading dose: 67 mcg/kg and continuous infusion of 0.61 mcg/kg/minute (Ramamoorthy, 1998). Further studies are needed before these proposed doses can routinely be used in the pediatric population.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure),\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 46(6):e1-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/16168273/pubmed\" id=\"16168273\" target=\"_blank\">",
"        16168273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"2005 American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC), Part 12: Pediatric Advanced Life Support, The American Heart Association Emergency Cardiovascular Care Committee,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 112(24 Suppl):IV58-77, 167-87.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barton P, Garcia J, Kouatli A, et al, \"Hemodynamic Effects of I.V. Milrinone Lactate in Pediatric Patients With Septic Shock. A Prospective Double-Blinded, Randomized, Placebo-Controlled, Interventional Study,\"",
"      <i>",
"       Chest",
"      </i>",
"      , 1996, 109(5):1302-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/8625683 /pubmed\" id=\"8625683 \" target=\"_blank\">",
"        8625683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang AC, Atz AM, Wernovsky G, et al, \"Milrinone: Systemic and Pulmonary Hemodynamic Effects in Neonates After Cardiac Surgery,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1995, 23(11):1907-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/7587268/pubmed\" id=\"7587268\" target=\"_blank\">",
"        7587268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cuffe MS, Califf RM, Adams KF Jr, et al, \"Short-Term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure: A Randomized Controlled Trial,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 287(12):1541-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/11911756/pubmed\" id=\"11911756\" target=\"_blank\">",
"        11911756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heart Failure Society of America, \"HFSA 2006 Comprehensive Heart Failure Practice Guideline,\"",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2006, 12(1):e1-122.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/16500560/pubmed\" id=\"16500560\" target=\"_blank\">",
"        16500560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoffman TM, Wernovsky G, Atz AM, et al, \"Efficacy and Safety of Milrinone in Preventing Low Cardiac Output Syndrome in Infants and Children After Corrective Surgery for Congenital Heart Disease,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 107(7):996-1002.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/12600913/pubmed\" id=\"12600913\" target=\"_blank\">",
"        12600913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoffman TM, Wernovsky G, Atz AM, et al, \"Prophylactic Intravenous Use of Milrinone After Cardiac Operation in Pediatrics (PRIMACORP) Study,\"",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2002, 143(1):15-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/11773907/pubmed\" id=\"11773907\" target=\"_blank\">",
"        11773907",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindsay CA, Barton P, Lawless S, et al, \"Pharmacokinetics and Pharmacodynamics of Milrinone Lactate in Pediatric Patients With Septic Shock,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1998, 132(2):329-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/9506650 /pubmed\" id=\"9506650 \" target=\"_blank\">",
"        9506650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paradisis M, Evans N, Kluckow M, et al, \"Pilot Study of Milrinone for Low Systemic Blood Flow in Very Preterm Infants,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2006, 148(3):306-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/16615956/pubmed\" id=\"16615956\" target=\"_blank\">",
"        16615956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramamoorthy C, Anderson GD, Williams GD, et al, \"Pharmacokinetics and Side Effects of Milrinone in Infants and Children After Open Heart Surgery,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1998, 86(2):283-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/60/25542/abstract-text/ 9459233 /pubmed\" id=\" 9459233 \" target=\"_blank\">",
"        9459233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12613 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25542=[""].join("\n");
var outline_f24_60_25542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196740\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054107\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443891\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054101\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196720\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196706\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054110\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472936\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196776\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054103\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054109\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196778\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196775\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054114\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054100\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054099\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299715\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221703\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196716\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13334385\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054106\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054098\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054112\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054113\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054115\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12613\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12613|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=related_link\">",
"      Milrinone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/22/20835?source=related_link\">",
"      Milrinone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_60_25543="MRI pubic ramus insufficiency fracture";
var content_f24_60_25543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    MRI pubic ramus insufficiency fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 466px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The T1 weighted MRI sequence of the pelvis (A, B) reveals a right sided parasymphysial dark band suggesting edema (white arrow). The STIR images (C) magnified and highlighted in D, confirm a faint fracture line (red arrow) associated with the edema. These findings are consistent with an insufficiency fracture of the right side of the pubic symphysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25543=[""].join("\n");
var outline_f24_60_25543=null;
var title_f24_60_25544="Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)";
var content_f24_60_25544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25544/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25544/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25544/contributors\">",
"     Jukka Mustonen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25544/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25544/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25544/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25544/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/60/25544/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with a hantavirus may lead to life threatening pulmonary and renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. In 1993, a highly fatal epidemic due to acute hantavirus infection in the American Southwest was associated with the rapid onset of respiratory failure, renal insufficiency, and fever [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The members of the Hantavirus genus (eg, Hantaan, Puumala, Seoul, Dobrava, Sin Nombre, and Andes virus) each produce different forms of clinical disease in humans. As an example, renal disease due to Puumala virus is relatively mild and is associated with a benign long-term prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Sin Nombre virus is the hantavirus found most frequently in the United States, which primarily induces a cardiopulmonary syndrome, as does the Andes virus found in South America [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/10\">",
"     10",
"    </a>",
"    ]. More severe renal disease can occur with infections by Hantaan and Dobrava virus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical syndromes caused by hantaviruses have also been known as epidemic hemorrhagic fever, hemorrhagic nephrosonephritis, Songo fever, Korean hemorrhagic fever, and nephropathia epidemica. In an attempt to avoid confusion, these diseases are now collectively referred to by the World Health Organization as \"hemorrhagic fever with renal syndrome\" (HFRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1,12\">",
"     1,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal disease associated with hantavirus infection will be reviewed here. The epidemiology and diagnosis of hantavirus infections, and hantavirus associated cardiopulmonary syndrome, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link\">",
"     \"Hantavirus cardiopulmonary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hantavirus infection is acquired by inhalation of aerosolized virus containing particles, or contact with urine, secretions or feces of infected rodents. Smoking, possibly by altering the conditions of the human airways, is a risk factor for Puumala virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The rodent vectors differ for each viral species but include mice, voles, shrews, and rats. Person-to-person transmission has been reported in Andes virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection with hantaviruses is associated with significant morbidity and mortality worldwide, although less than one-fourth of cases have a severe course [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. Overall mortality from HFRS varies widely, from 0.5 percent with the milder European forms of the disease, to as high as 5 to 10 percent for Korean hemorrhagic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1,6,11\">",
"     1,6,11",
"    </a>",
"    ]. Current supportive care has had a substantial positive effect upon mortality in this illness. For patients with severe HFRS, for example, mortality rates have decreased from 10 to 15 percent in the 1960s to current rates of less than five percent with advanced supportive care.",
"   </p>",
"   <p>",
"    Many cases have been reported in Europe and Asia, including Scandinavia, the Balkans, and Korea. In addition, the 1999 war in the Balkans was associated with a resurgence of cases, most of which resulted from the exposure of soldiers to rodents in the field [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple areas of the United States may also harbor reservoirs for the Sin Nombre hantavirus. Serologically proven disease due to HFRS strains has been documented in Baltimore due to a heavily infested rodent population, although the attack rate was low [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/17\">",
"     17",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased vascular permeability appears to play a general role in the pathogenesis of severe hantavirus infection. This is suggested clinically by an increase in hematocrit and a decrease in serum protein levels, and tracer studies have confirmed a generalized vascular leak [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Additional findings are similar to those of septic shock, including a decrease in peripheral vascular resistance and an increase in cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4920?source=see_link\">",
"     \"Pathogenesis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An abrupt decline in glomerular filtration rate is often observed among patients with hantavirus infection. Intrarenal events play an important role in the development of renal failure in HFRS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1\">",
"     1",
"    </a>",
"    ]. The following contributing factors have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Damage to vascular endothelium",
"     </li>",
"     <li>",
"      Initiation of tubular and interstitial damage by cytokines and other humoral factors (such as tumor necrosis factor), causing acute tubulointerstitial nephritis. This is corroborated by the increased expression of cytokines in the peritubular areas on histologic specimens [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/19\">",
"       19",
"      </a>",
"      ], and by the correlation of urinary excretion of interleukin-6 with the amount of proteinuria (eg, severity of damage) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic factors may predispose some individuals to the development of severe renal involvement associated with HFRS due to Puumala virus because of an enhanced immune response to the virus [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1,21,22\">",
"       1,21,22",
"      </a>",
"      ]. As an example, adults with HLA B8 and DR3 alleles develop acute renal failure requiring dialysis more often than those without these alleles [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/22\">",
"       22",
"      </a>",
"      ]; in contrast, patients with HLA B27 have milder disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/23\">",
"       23",
"      </a>",
"      ]. A similar association between HLA B8 and DR3 and severity of disease has not been noted in children, perhaps because the overall clinical course of Puumala virus infection is milder than in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the exact role of the viral infection is unclear. As an example, although hantaviruses have been shown to infect human endothelial cells using beta3 integrins, they are not necessarily cytotoxic, and similar endothelial cell infection has been documented with many viruses that do not cause severe vascular damage (eg, herpes simplex virus, adenovirus, measles virus).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The virus can be demonstrated by polymerase chain reaction in kidney biopsy material [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/26\">",
"     26",
"    </a>",
"    ]. The most prominent renal histopathologic finding of hantavirus infection is an acute tubulointerstitial nephritis, with the inflammatory infiltrate composed predominantly of mononuclear cells and CD8 lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/27\">",
"     27",
"    </a>",
"    ]. Other common interstitial changes include congestion and dilatation of the medullary vessels, hemorrhage into the medullary tissues, interstitial edema, and tubular cell necrosis and degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/3,26,27\">",
"     3,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the often marked proteinuria, histologic changes in the glomeruli are typically mild. Light microscopy may demonstrate slight mononuclear hypercellularity and mesangial proliferation, and immunohistochemistry may reveal occasional immunoglobulin and complement deposits in the glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/3,27-29\">",
"     3,27-29",
"    </a>",
"    ]. However, mesangiocapillary glomerulonephritis shortly after Puumala virus infection has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic HFRS has several prominent features, including [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1-6,11,31\">",
"     1-6,11,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Hemorrhage",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Renal failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical course, however, can be extremely variable, and some infected individual are asymptomatic. The severity of illness manifestations tends to vary based upon the strain of infecting hantavirus, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Puumala virus infection, seen mostly in Europe, can present with fever, loin or abdominal pain, nausea and vomiting, malaise, conjunctival hemorrhage, headache, and acute myopia associated with headache [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1-3,11\">",
"       1-3,11",
"      </a>",
"      ]. Some patients develop hypotension and severe oliguric acute renal failure. Abnormal laboratory values include a leukocytosis, thrombocytopenia, an elevated LDH, and slightly elevated liver function tests. Enhanced thrombin formation and fibrinolysis are also characteristic [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/32\">",
"       32",
"      </a>",
"      ]. An elevated serum creatinine is universal, and proteinuria and microscopic hematuria are very common. Abnormal electro- and echocardiographic findings are common in HFRS patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. The clinical picture of Dobrava infection is similar, but the symptoms are somewhat more severe [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/11,31,35-39\">",
"       11,31,35-39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Manifestations of HFRS due to Asian strains are more severe [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1,5,6\">",
"       1,5,6",
"      </a>",
"      ]. In addition to the findings noted with Puumala virus infection, over one-third of patients are hypotensive; almost two-thirds develop oliguria, many of whom may require dialysis; laboratory abnormalities are more severe; and disseminated intravascular coagulation (DIC) can be observed. Among the Asian HFRS, disease due to Hantaan virus is more severe than with the Seoul virus, with a greater likelihood of shock and renal failure requiring dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Sin Nombre virus strain in the United States and Andes virus in South America have been mostly associated with respiratory failure; initial cases had no or relatively mild renal involvement (low grade proteinuria and hematuria in 50 percent, and a modest increase in the serum creatinine to &lt; 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [220",
"      <span class=\"nowrap\">",
"       &micro;mol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/7,10\">",
"       7,10",
"      </a>",
"      ]. However, cases with more severe renal failure including requiring dialysis, have since been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link\">",
"       \"Hantavirus cardiopulmonary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement includes proteinuria, hematuria and reduced glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transient nonselective proteinuria (glomerular and tubular) is found in almost all patients with HFRS caused by various hantaviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1,43-45\">",
"     1,43-45",
"    </a>",
"    ]. This was best described in a series of 126 hospitalized patients with Puumala virus infection; protein excretion ranged from 0 to 12.3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (mean 2.6",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    and 25 percent of patients had nephrotic range proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microscopic hematuria is observed in 58 to 85 percent of patients with Puumala virus and in 85 to 100 percent of patients with Hantaan and Dobrava virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. Macroscopic hematuria is uncommon.",
"   </p>",
"   <p>",
"    Most patients hospitalized with HFRS have a transient reduction in GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/6,31,44\">",
"     6,31,44",
"    </a>",
"    ]. Dialysis is infrequently required by patients infected with the Puumala virus (five percent), but may be required by 20 to 40 percent of patients infected with the Seoul, Dobrava, or Hantaan virus (most likely due to the greater overall severity of illness) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. The severity of renal failure in Puumala virus infection associates with high plasma interleukin 6 (IL-6) and serum indoleamine 2,3-dioxygenase (IDO) activity, while high plasma C-reactive protein may be a protective factor for renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Phases of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe HFRS typically progress sequentially from fever, to abrupt hypotension and clinical shock, and then to oliguria. As thrombocytopenia and DIC develop, findings of diffuse hemorrhage may appear, including petechiae, ecchymoses, hematemesis, hemoptysis, and melena. If patients survive this acute period, they subsequently enter a diuretic phase by day 10 to 14 and then a convalescent phase that often lasts many weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Renal prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients generally return to baseline glomerular filtration rate (GFR) following an episode of acute renal failure related to hantavirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/1,6,9,48\">",
"     1,6,9,48",
"    </a>",
"    ]. However, there are case reports of residual decreased GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/12,49,50\">",
"     12,49,50",
"    </a>",
"    ], and of a possible association with subsequent hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/9,51-54\">",
"     9,51-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term sequelae were perhaps best illustrated in observational studies five, six, and ten years after Puumala virus-induced nephropathy. At five to six years, affected patients had a higher GFR, more glomerular and tubular proteinuria, and higher blood pressure compared with healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/8,55\">",
"     8,55",
"    </a>",
"    ]; however, hyperfiltration and proteinuria resolved by ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/9\">",
"     9",
"    </a>",
"    ]. The severity of acute Puumala virus infection does not predict the long-term outcome of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory failure was a prominent finding in some cases overseas and in the epidemic in the southwestern United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Patients presented with a fever, flushing, pharyngeal and conjunctival congestion, myalgias, headache, cough, and then rapid respiratory failure. Respiratory failure was much more significant than hemorrhage or renal failure, and was thought to be due to noncardiogenic pulmonary edema caused by a diffuse capillary leak syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link\">",
"     \"Hantavirus cardiopulmonary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, patients with HFRS without significant pulmonary symptoms may also have abnormal chest radiographic findings. As an example, among 125 patients hospitalized with Puumala virus infection, 28 percent had abnormal chest radiographs (pleural effusion, atelectasis and interstitial infiltrates) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/57\">",
"     57",
"    </a>",
"    ]. Frank pulmonary edema was rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of hemorrhagic fever with renal syndrome (HFRS) should be considered in patients with high fever, headache, abdominal pain and back pain; respiratory symptoms need not be present.",
"   </p>",
"   <p>",
"    A history should elicit whether the patient is at increased risk of exposure to rodents either due to occupation (eg, farming, forestry, animal trapping) or other situation (eg, military activity, crisis conditions, camping) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory findings suggestive of the diagnosis include leukocytosis, elevated C-reactive protein, thrombocytopenia, elevated serum creatinine level, proteinuria and hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of hantavirus infection can be confirmed with serologic tests. By the time symptoms are evident, patients usually have antiviral antibodies of the IgM class, and most also have IgG antibodies. The diagnosis of hantavirus infections is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of kidney disease in HFRS is based upon the typical clinical and laboratory manifestations (proteinuria, hematuria, elevated serum creatinine), in conjunction with the serological evidence of a recent hantavirus infection. A kidney biopsy is not required, but may be needed if the clinical course of the kidney disease is not typical of HFRS (eg, kidney function usually recovers following clinical recovery) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/30,58,59\">",
"     30,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kidney ultrasound may demonstrate an increase in the length of the kidneys and in the resistive indices, and perirenal fluid collections (as well as pleural, pericardial, ascitic fluid) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/60\">",
"     60",
"    </a>",
"    ]. These findings are nonspecific, but correlate with the severity of kidney failure and volume overload.",
"   </p>",
"   <p>",
"    The differential diagnosis includes other infections associated with acute renal failure, such as leptospirosis, and noninfectious acute interstitial nephritis caused by drugs (eg, nonsteroidal antiinflammatory drugs, NSAIDs). Other non-infectious etiologies include diseases associated with pulmonary hemorrhage, such as granulomatosis with polyangiitis (Wegener&rsquo;s) and Goodpasture's syndrome. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the vector is the rodent, the risk of infection may be minimized by avoiding areas where rodents live in large numbers, and by preventing rodent inhabitation near homes and work areas. The risk of transmission is obviously greater indoors (houses, cabins, barns) where rodents may be seeking food or shelter from the cold. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link&amp;anchor=H18#H18\">",
"     \"Hantavirus cardiopulmonary syndrome\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A vaccine has been developed in Korea but it is uncertain whether it would be protective: although high IgG titers developed in nearly 100 percent of volunteers after a course of three vaccines, titers declined rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/12\">",
"     12",
"    </a>",
"    ]. Other vaccines are under development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link&amp;anchor=H19#H19\">",
"     \"Hantavirus cardiopulmonary syndrome\", section on 'Vaccine development'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no specific antiviral therapies for hantavirus. Although one prospective double-blinded study of 242 patients with serologically proven infection found that intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    therapy resulted in a reduction in mortality, other studies did not confirm these benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link&amp;anchor=H17#H17\">",
"     \"Hantavirus cardiopulmonary syndrome\", section on 'Antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy is therefore restricted to supportive care. Headache and backache may require analgesics, but NSAIDS should be avoided. Thrombocytopenia may require platelet transfusion, and corticosteroids have been tried in a case of protracted thrombocytopenia associated with HFRS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25544/abstract/62\">",
"     62",
"    </a>",
"    ]. Dialysis should be provided for the usual indications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients fully recover if there is adequate supportive care (which can require the intensive care unit and dialysis) for often life-threatening complications. Patients with acute renal failure, even if dialysis requiring, usually recover if they survive the initial severe illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal manifestations vary depending on the type of hantavirus infection, being more severe with Hantaan and Dobrava virus infection, and milder with Puumala virus infection. Sin Nombre virus, the hantavirus found in the United States, primarily induces hantavirus cardiopulmonary syndrome (HCPS), although severe disease may lead to acute renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=see_link\">",
"       \"Epidemiology and diagnosis of hantavirus infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=see_link\">",
"       \"Hantavirus cardiopulmonary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hantavirus infection is acquired by inhalation of aerosolized virus containing particles or other contact with urine, secretions, or feces of infected rodents (eg, mice, voles, shrews, and rats, depending on the hantavirus genus). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased vascular permeability appears to play a general role in the pathogenesis of severe hantavirus infection. An abrupt decline in glomerular filtration rate is thought to be related in part to damage to the vascular endothelium and cytokine-induced tubular and interstitial damage. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis of renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The virus can be demonstrated by polymerase chain reaction in kidney biopsy material. The most prominent renal histopathologic finding of hantavirus infection is an acute tubulointerstitial nephritis, sometimes with interstitial hemorrhage. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe, classic HFRS progress sequentially from fever with hemorrhage, to hypotension and shock, then oliguric acute renal failure. The clinical course, however, can be extremely variable, and some infected patients are asymptomatic. Renal manifestations include proteinuria, hematuria and reduced glomerular filtration rate (GFR). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Phases of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is based upon a history of potential exposure to rodents, laboratory findings suggestive of the diagnosis (leukocytosis, thrombocytopenia, elevated serum creatinine level, proteinuria and hematuria), and is confirmed with serologic testing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=see_link\">",
"       \"Epidemiology and diagnosis of hantavirus infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are no specific antiviral therapies for hantavirus infection, thus therapy is restricted to supportive care. NSAIDs should be avoided, as they can contribute to acute renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"       \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dialysis should be provided for the appropriate indications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who survive typically recover kidney function. Some patients may have persistent proteinuria, and hypertension. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Renal prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/1\">",
"      Cosgriff TM, Lewis RM. Mechanisms of disease in hemorrhagic fever with renal syndrome. Kidney Int Suppl 1991; 35:S72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/2\">",
"      Tkachenko EA, Lee HW. Etiology and epidemiology of hemorrhagic fever with renal syndrome. Kidney Int Suppl 1991; 35:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/3\">",
"      Collan Y, Mihatsch MJ, L&auml;hdevirta J, et al. Nephropathia epidemica: mild variant of hemorrhagic fever with renal syndrome. Kidney Int Suppl 1991; 35:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/4\">",
"      van Ypersele de Strihou C. Clinical features of hemorrhagic fever with renal syndrome in Europe. Kidney Int Suppl 1991; 35:S80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/5\">",
"      Takeuchi T, Yamamoto T, Itoh M, et al. Clinical studies on hemorrhagic fever with renal syndrome found in Nagoya City University Medical School. Kidney Int Suppl 1991; 35:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/6\">",
"      Lee JS. Clinical features of hemorrhagic fever with renal syndrome in Korea. Kidney Int Suppl 1991; 35:S88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/7\">",
"      Duchin JS, Koster FT, Peters CJ, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med 1994; 330:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/8\">",
"      M&auml;kel&auml; S, Ala-Houhala I, Mustonen J, et al. Renal function and blood pressure five years after puumala virus-induced nephropathy. Kidney Int 2000; 58:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/9\">",
"      Miettinen MH, M&auml;kel&auml; SM, Ala-Houhala IO, et al. Ten-year prognosis of Puumala hantavirus-induced acute interstitial nephritis. Kidney Int 2006; 69:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/10\">",
"      Khaiboullina SF, Morzunov SP, St Jeor SC. Hantaviruses: molecular biology, evolution and pathogenesis. Curr Mol Med 2005; 5:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/11\">",
"      Vapalahti O, Mustonen J, Lundkvist A, et al. Hantavirus infections in Europe. Lancet Infect Dis 2003; 3:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/12\">",
"      Muranyi W, Bahr U, Zeier M, van der Woude FJ. Hantavirus infection. J Am Soc Nephrol 2005; 16:3669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/13\">",
"      Van Loock F, Thomas I, Clement J, et al. A case-control study after a hantavirus infection outbreak in the south of Belgium: who is at risk? Clin Infect Dis 1999; 28:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/14\">",
"      Vapalahti K, Virtala AM, Vaheri A, Vapalahti O. Case-control study on Puumala virus infection: smoking is a risk factor. Epidemiol Infect 2010; 138:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/15\">",
"      Enr&iacute;a D, Padula P, Segura EL, et al. Hantavirus pulmonary syndrome in Argentina. Possibility of person to person transmission. Medicina (B Aires) 1996; 56:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/16\">",
"      Bugert JJ, Welzel TM, Zeier M, Darai G. Hantavirus infection--haemorrhagic fever in the Balkans--potential nephrological hazards in the Kosovo war. Nephrol Dial Transplant 1999; 14:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/17\">",
"      Glass GE, Watson AJ, LeDuc JW, Childs JE. Domestic cases of hemorrhagic fever with renal syndrome in the United States. Nephron 1994; 68:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/18\">",
"      Papadimitriou M. Hantavirus nephropathy. Kidney Int 1995; 48:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/19\">",
"      Temonen M, Mustonen J, Helin H, et al. Cytokines, adhesion molecules, and cellular infiltration in nephropathia epidemica kidneys: an immunohistochemical study. Clin Immunol Immunopathol 1996; 78:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/20\">",
"      M&auml;kel&auml; S, Mustonen J, Ala-Houhala I, et al. Urinary excretion of interleukin-6 correlates with proteinuria in acute Puumala hantavirus-induced nephritis. Am J Kidney Dis 2004; 43:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/21\">",
"      M&auml;kel&auml; S, Mustonen J, Ala-Houhala I, et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-alpha(-308) G/A polymorphism. J Infect Dis 2002; 186:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/22\">",
"      Mustonen J, Partanen J, Kanerva M, et al. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. Kidney Int 1996; 49:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/23\">",
"      Mustonen J, Partanen J, Kanerva M, et al. Association of HLA B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus. Scand J Immunol 1998; 47:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/24\">",
"      Ahlm C, Settergren B, Gothefors L, Juto P. Nephropathia epidemica (hemorrhagic fever with renal syndrome) in children: clinical characteristics. Pediatr Infect Dis J 1994; 13:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/25\">",
"      Mustonen J, Huttunen NP, Partanen J, et al. Human leukocyte antigens B8-DRB1*03 in pediatric patients with nephropathia epidemica caused by Puumala hantavirus. Pediatr Infect Dis J 2004; 23:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/26\">",
"      Heiske A, Anheier B, Pilaski J, et al. Polymerase chain reaction detection of Puumala virus RNA in formaldehyde-fixed biopsy material. Kidney Int 1999; 55:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/27\">",
"      Mustonen J, Helin H, Pietil&auml; K, et al. Renal biopsy findings and clinicopathologic correlations in nephropathia epidemica. Clin Nephrol 1994; 41:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/28\">",
"      Grcevska L, Polenakovi M, Oncevski A, et al. Different pathohistological presentations of acute renal involvement in Hantaan virus infection: report of two cases. Clin Nephrol 1990; 34:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/29\">",
"      Ferluga D, Vizjak A. Hantavirus nephropathy. J Am Soc Nephrol 2008; 19:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/30\">",
"      Mustonen J, M&auml;kel&auml; S, Helin H, et al. Mesangiocapillary glomerulonephritis caused by Puumala hantavirus infection. Nephron 2001; 89:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/31\">",
"      Settergren B, Juto P, Trollfors B, et al. Hemorrhagic complications and other clinical findings in nephropathia epidemica in Sweden: a study of 355 serologically verified cases. J Infect Dis 1988; 157:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/32\">",
"      Laine O, M&auml;kel&auml; S, Mustonen J, et al. Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection. Thromb Res 2010; 126:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/33\">",
"      Puljiz I, Kuzman I, Markoti A, et al. Electrocardiographic changes in patients with haemorrhagic fever with renal syndrome. Scand J Infect Dis 2005; 37:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/34\">",
"      Makela S, Kokkonen L, Ala-Houhala I, et al. More than half of the patients with acute Puumala hantavirus infection have abnormal cardiac findings. Scand J Infect Dis 2009; 41:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/35\">",
"      Avsic-Zupanc T, Petrovec M, Furlan P, et al. Hemorrhagic fever with renal syndrome in the Dolenjska region of Slovenia--a 10-year survey. Clin Infect Dis 1999; 28:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/36\">",
"      Papa A, Antoniadis A. Hantavirus infections in Greece--an update. Eur J Epidemiol 2001; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/37\">",
"      Markoti A, Nichol ST, Kuzman I, et al. Characteristics of Puumala and Dobrava infections in Croatia. J Med Virol 2002; 66:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/38\">",
"      Huki M, Valjevac A, Tulumovic D, et al. Pathogenicity and virulence of the present hantaviruses in Bosnia and Herzegovina: the impact on renal function. Eur J Clin Microbiol Infect Dis 2011; 30:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/39\">",
"      Tulumovic D, Imamovic G, Mesic E, et al. Comparison of the effects of Puumala and Dobrava viruses on early and long-term renal outcomes in patients with haemorrhagic fever with renal syndrome. Nephrology (Carlton) 2010; 15:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/40\">",
"      Passaro DJ, Shieh WJ, Hacker JK, et al. Predominant kidney involvement in a fatal case of hantavirus pulmonary syndrome caused by Sin Nombre virus. Clin Infect Dis 2001; 33:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/41\">",
"      Dara SI, Albright RC, Peters SG. Acute sin nombre hantavirus infection complicated by renal failure requiring hemodialysis. Mayo Clin Proc 2005; 80:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/42\">",
"      Hjelle B, Goade D, Torrez-Martinez N, et al. Hantavirus pulmonary syndrome, renal insufficiency, and myositis associated with infection by Bayou hantavirus. Clin Infect Dis 1996; 23:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/43\">",
"      Ala-Houhala I, Koskinen M, Ahola T, et al. Increased glomerular permeability in patients with nephropathia epidemica caused by Puumala hantavirus. Nephrol Dial Transplant 2002; 17:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/44\">",
"      Settergren B, Trollfors B, Fasth A, et al. Glomerular filtration rate and tubular involvement during acute disease and convalescence in patients with nephropathia epidemica. J Infect Dis 1990; 161:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/45\">",
"      Matthaeus T, Fries J, Weber M, Schulze-Lohoff E. [Glomerular-type proteinuria in hantavirus nephritis]. Med Klin (Munich) 2004; 99:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/46\">",
"      Outinen TK, M&auml;kel&auml; SM, Ala-Houhala IO, et al. The severity of Puumala hantavirus induced nephropathia epidemica can be better evaluated using plasma interleukin-6 than C-reactive protein determinations. BMC Infect Dis 2010; 10:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/47\">",
"      Outinen, TK, Makela, SM, Ala-Houhala, IO, et, al. High activity of indoleamine 2,3-dioxygenase is associated with renal insufficiency in Puumala hantavirus induced nephropathia epidemica. J Med Virol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/48\">",
"      L&auml;hdevirta J, Collan Y, Jokinen EJ, Hiltunen R. Renal sequelae to nephropathia epidemica. Acta Pathol Microbiol Scand A 1978; 86:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/49\">",
"      Novo R, Gagnadoux MF, Le Guenno Y, et al. Chronic renal failure after Puumala virus infection. Pediatr Nephrol 1999; 13:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/50\">",
"      Pergam SA, Schmidt DW, Nofchissey RA, et al. Potential renal sequelae in survivors of hantavirus cardiopulmonary syndrome. Am J Trop Med Hyg 2009; 80:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/51\">",
"      Kleinknecht D, Rollin PE. Hypertension after hemorrhagic fever with renal syndrome. Nephron 1992; 61:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/52\">",
"      Glass GE, Watson AJ, LeDuc JW, et al. Infection with a ratborne hantavirus in US residents is consistently associated with hypertensive renal disease. J Infect Dis 1993; 167:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/53\">",
"      RUBINI ME, JABLON S, McDOWELL ME. Renal residuals of acute epidemic hemorrhagic fever. Arch Intern Med 1960; 106:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/54\">",
"      Niklasson B, Hellsten G, LeDuc J. Hemorrhagic fever with renal syndrome: a study of sequelae following nephropathia epidemica. Arch Virol 1994; 137:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/55\">",
"      Miettinen MH, Makela SM, Ala-Houhala IO, et al. Tubular proteinuria and glomerular filtration 6 years after puumala hantavirus-induced acute interstitial nephritis. Nephron Clin Pract 2009; 112:c115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/56\">",
"      Miettinen MH, M&auml;kel&auml; SM, Ala-Houhala IO, et al. The severity of acute Puumala hantavirus infection does not predict the long-term outcome of patients. Nephron Clin Pract 2010; 116:c89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/57\">",
"      Kanerva M, Paakkala A, Mustonen J, et al. Pulmonary involvement in nephropathia epidemica: radiological findings and their clinical correlations. Clin Nephrol 1996; 46:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/58\">",
"      Kim S, Sung SH, An HR, et al. A case report of crescentic glomerulonephritis associated with Hantaan virus infection. Nephrol Dial Transplant 2010; 25:2790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/59\">",
"      Miettinen, M, Makela, S, Haapala, M, et, al. Glomerulonephritis emerging shortly after Puumala hantavirus infection: a report on seven patients. Clin Nephrol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/60\">",
"      Paakkala A, Kallio T, Huhtala H, et al. Renal ultrasound findings and their clinical associations in nephropathia epidemica. Analysis of quantitative parameters. Acta Radiol 2002; 43:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/61\">",
"      Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25544/abstract/62\">",
"      Dunst R, Mettang T, Kuhlmann U. Severe thrombocytopenia and response to corticosteroids in a case of nephropathia epidemica. Am J Kidney Dis 1998; 31:116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7240 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25544=[""].join("\n");
var outline_f24_60_25544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS OF RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Phases of disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Renal prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13848?source=related_link\">",
"      Epidemiology and diagnosis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38119?source=related_link\">",
"      Hantavirus cardiopulmonary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4920?source=related_link\">",
"      Pathogenesis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4696?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_60_25545="Paroxysmal hemicrania: Clinical features and diagnosis";
var content_f24_60_25545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Paroxysmal hemicrania: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25545/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25545/contributors\">",
"     Manjit S Matharu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25545/contributors\">",
"     Anna S Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25545/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25545/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25545/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25545/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/60/25545/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), and short-lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite their common elements, the TACs differ in attack duration and frequency, as well as the response to therapy (",
"    <a class=\"graphic graphic_table graphicRef65541 \" href=\"UTD.htm?41/12/42188\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cluster headache has the longest attack duration and relatively low attack frequency",
"     </li>",
"     <li>",
"      Paroxysmal hemicrania has intermediate duration and intermediate attack frequency",
"     </li>",
"     <li>",
"      SUNCT has the shortest attack duration and the highest attack frequency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of recognizing these syndromes resides in their excellent but highly selective response to treatment. Hence, early diagnosis will often lead to appropriate treatment and rapid relief of pain. Paroxysmal hemicrania, unlike cluster headache and SUNCT, responds in a dramatic and absolute fashion to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, clinical features, and diagnosis of paroxysmal hemicrania. Management is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9112?source=see_link\">",
"     \"Paroxysmal hemicrania: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other trigeminal autonomic cephalalgias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=see_link\">",
"     \"Pathophysiology of the trigeminal autonomic cephalalgias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal hemicrania was first described in 1974 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/4\">",
"     4",
"    </a>",
"    ]. The initial cases were characterized by daily headaches for years without remission, and the condition was termed \"chronic paroxysmal hemicrania\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/5\">",
"     5",
"    </a>",
"    ]. Subsequently, it became apparent that not all patients experienced a chronic, unremitting course; in some patients, discrete headache bouts were separated by prolonged pain-free remissions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/1,6-11\">",
"     1,6-11",
"    </a>",
"    ]. This remitting pattern was named episodic paroxysmal hemicrania.",
"   </p>",
"   <p>",
"    The first edition of the International Headache Society (IHS) classification in 1988 recognized and gave diagnostic criteria for chronic paroxysmal hemicrania [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/12\">",
"     12",
"    </a>",
"    ]. The second edition of the IHS classification in 2004 introduced the umbrella term \"paroxysmal hemicrania\" and recognized both an episodic and a chronic form of this type of headache [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal hemicrania is a rare condition. The exact incidence and prevalence of paroxysmal hemicrania are not known, but it has been reported in various parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/13-15\">",
"     13-15",
"    </a>",
"    ] and affects different races [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By one estimate, the prevalence of paroxysmal hemicrania is 1 to 3 percent of the prevalence of cluster headache [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18\">",
"     18",
"    </a>",
"    ]. Given that the prevalence of cluster headache is approximately 1 per 500 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/19\">",
"     19",
"    </a>",
"    ], the prevalence of paroxysmal hemicrania would be approximately 1 per 25,000. However, epidemiologic data are scarce and many cases of paroxysmal hemicrania are probably still overlooked.",
"   </p>",
"   <p>",
"    In a headache epidemiology study of 1838 adults from Norway, no definite cases of paroxysmal hemicrania were confirmed, although a possible variant of chronic paroxysmal hemicrania was identified in one individual (0.05 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/20\">",
"     20",
"    </a>",
"    ]. In contrast, cluster headache was identified in seven (0.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sex distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective surveys suggested a female predominance in paroxysmal hemicrania [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18,22,23\">",
"     18,22,23",
"    </a>",
"    ], but a later prospective study found that the female:male ratio is approximately 1 to 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Age of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal hemicrania may begin at any age, although onset usually occurs during adulthood. The mean age of onset ranges from 34 to 41 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18,23,24\">",
"     18,23,24",
"    </a>",
"    ]. The youngest age at onset was 1 year and the oldest was 81 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18,25\">",
"     18,25",
"    </a>",
"    ]. In one case series, episodic paroxysmal hemicrania began earlier (mean 27 years) than chronic paroxysmal hemicrania (mean 37 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical phenotype of paroxysmal hemicrania is highly characteristic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18,22,23,26,27\">",
"     18,22,23,26,27",
"    </a>",
"    ]. Patients typically have unilateral, brief, severe attacks of pain associated with cranial autonomic features that recur several times per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Side, laterality, severity, and character of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The headache of paroxysmal hemicrania is strictly unilateral. It occurs without side shift in &gt;95 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pain is most often in the ophthalmic trigeminal distribution (V1), but it can be extratrigeminal. The maximum pain is usually centered on the orbital, retroorbital, temporal, and frontal regions. Less often, the pain involves the occipital region, maxillary region, neck, ear, and teeth [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"     24",
"    </a>",
"    ]. The pain may occasionally radiate into the ipsilateral shoulder and arm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pain is typically excruciating in severity and is described most often with the terms sharp, stabbing, throbbing, shooting, burning, or boring [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Duration of the individual attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The headache usually lasts 2 to 30 minutes, but may go on for up to two hours.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 105 attacks, the mean duration was 13 minutes, with a range of 3 to 46 minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/26,28\">",
"       26,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another prospective study of 31 patients reported a mean duration of 17 minutes, with a range of 10 seconds to four hours [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two retrospective studies, consisting of 84 and 74 patients, reported mean attack durations of 21 minutes (range 2 to 120 minutes) and 26 minutes, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18,23\">",
"       18,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The headache has an abrupt onset and cessation. Interictal discomfort or pain is present in up to one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Associated features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attacks of paroxysmal hemicrania typically occur in association with ipsilateral cranial autonomic features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lacrimation, conjunctival injection, rhinorrhea, nasal congestion, ptosis, or facial flushing frequently accompany the headache [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Eyelid edema, forehead or facial sweating, aural fullness, aural swelling, miosis, or mydriasis are less frequently reported [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Photophobia and nausea may accompany some attacks, though vomiting and phonophobia are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18\">",
"     18",
"    </a>",
"    ]. In a retrospective study of patients with chronic paroxysmal hemicrania, at least one migrainous feature of photophobia, nausea, or vomiting during an attack was present in 27 of 31 (87 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/23\">",
"     23",
"    </a>",
"    ]. In a prospective study, photophobia accompanying chronic paroxysmal hemicrania was unilateral and on the same side as the pain in four of six patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/29\">",
"     29",
"    </a>",
"    ]. Similarly, photophobia was unilateral in approximately one-half of patients with other trigeminal autonomic cephalalgias. In contrast, photophobia associated with migraine was unilateral in less than 10 percent of cases.",
"   </p>",
"   <p>",
"    Agitation and pacing are often present during attacks of paroxysmal hemicrania. A prospective study of 31 patients found that agitation or restlessness was present in 25 patients (80 percent) during episodes of pain, while eight (25 percent) were aggressive, more often verbally than physically [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"     24",
"    </a>",
"    ]. In an earlier retrospective study, approximately one-half of patients with paroxysmal hemicrania attacks assumed the pacing activity usually seen with cluster headaches, while the other half preferred to sit or lie still [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Frequency and periodicity of attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;In paroxysmal hemicrania, the attacks tend to occur at a high frequency, with a range from 1 to 40 daily.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 31 patients, the mean attack frequency was 11 (range 2 to 50) in 24 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/30\">",
"       30",
"      </a>",
"      ]. An earlier prospective study of 105 paroxysmal hemicrania attacks in five patients reported a mean attack frequency of 14 (range 4 to 38) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two retrospective studies consisting of 84 and 74 patients, the mean attack frequency was 11 (range 2 to 40) and 6 daily, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18,23\">",
"       18,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The attacks occur regularly throughout the 24-hour period without a preponderance of nocturnal attacks as is seen in cluster headache. However, nocturnal attacks associated with the rapid eye movement (REM) phase of sleep have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most attacks of paroxysmal hemicrania are spontaneous. However, a number of attack triggers have been reported. In a prospective report of 31 patients, the most common triggers of paroxysmal hemicrania attacks were stress or relaxation after stress in eight patients (26 percent), exercise in seven (23 percent), alcohol in six (19 percent), and neck movement in six (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"     24",
"    </a>",
"    ]. Cutaneous triggering, such as touching the skin, chewing, or talking, is uncommon with paroxysmal hemicrania [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between menstruation and paroxysmal hemicrania attacks, if any, is undetermined. Oral contraceptive medications do not seem to influence the attack frequency. In some women, paroxysmal hemicrania attacks improved or disappeared during pregnancy but reappeared after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. There is no reported effect of menopause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atypical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are case reports documenting unusual clinical features of paroxysmal hemicrania, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Side-alternating attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/34-37\">",
"       34-37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bilateral, short-lasting, frequent,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      -responsive headaches without cranial autonomic features [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. While these cases were reported as bilateral paroxysmal hemicrania, they may instead represent bilateral paroxysmal cephalalgia, a novel indomethacin-responsive primary headache syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unilateral paroxysmal hemicrania with no autonomic features [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/34,35,42\">",
"       34,35,42",
"      </a>",
"      ] and other cases of paroxysmal hemicrania with dissociation between pain and autonomic features [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/37,43\">",
"       37,43",
"      </a>",
"      ]. Alternatively, it is possible that current criteria do not recognize the breadth of cranial autonomic features that may be associated with paroxysmal hemicrania. As an example, the sense of aural fullness reported by two patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/42\">",
"       42",
"      </a>",
"      ] may be part of the spectrum of symptoms associated with cranial parasympathetic autonomic activation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paroxysmal hemicrania manifested by ear pain and a sensation of external acoustic meatus obstruction, and paroxysmal hemicrania associated with red ear syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/42\">",
"       42",
"      </a>",
"      ]. The red ear syndrome is a rare condition characterized by otalgia and associated autonomic phenomena, including cutaneous erythema of the ear ipsilateral to the pain [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Primarily extratrigeminal pain with paroxysmal hemicrania [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Typical migrainous aura occurring in association with paroxysmal hemicrania attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal hemicrania has been observed in association with other headache disorders, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trigeminal neuralgia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/47-52\">",
"       47-52",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link\">",
"       \"Trigeminal neuralgia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cluster headache [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/14,53-55\">",
"       14,53-55",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"       \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/23,56,57\">",
"       23,56,57",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tension-type headache [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/23\">",
"       23",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=see_link\">",
"       \"Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary stabbing headache [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/58\">",
"       58",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"       \"Primary stabbing headache\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Primary cough headache [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/59\">",
"       59",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=see_link\">",
"       \"Primary cough headache\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hemicrania continua [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/60\">",
"       60",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Hemicrania continua'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Typically, each type of headache must be treated for the patient to be headache free. Exceptions are primary stabbing headache and primary cough headache, which are also responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of paroxysmal hemicrania is based upon a compatible clinical history in the setting of a normal neurologic examination. The diagnosis is confirmed by an optimum therapeutic trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Since a relatively high number of secondary cases of paroxysmal hemicrania have been reported, an MRI scan of the brain should be routinely performed in all patients with paroxysmal hemicrania to exclude a structural brain lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The revised International Classification of Headache Disorders II (ICHD-2) criteria for paroxysmal hemicrania are as follows (",
"    <a class=\"graphic graphic_table graphicRef58505 \" href=\"UTD.htm?11/2/11308\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    At least 20 attacks fulfilling the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe unilateral orbital, supraorbital, or temporal pain lasting 2 to 30 minutes",
"     </li>",
"     <li>",
"      Headache is accompanied by at least one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ipsilateral conjunctival injection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lacrimation",
"     </li>",
"     <li>",
"      Ipsilateral nasal congestion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rhinorrhea",
"     </li>",
"     <li>",
"      Ipsilateral eyelid edema",
"     </li>",
"     <li>",
"      Ipsilateral forehead and facial sweating",
"     </li>",
"     <li>",
"      Ipsilateral miosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ptosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attacks have a frequency &gt;5 per day for more than half the time, although periods with lower frequency may occur",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ICHD-2 criteria for paroxysmal hemicrania also require that the attacks are prevented completely by therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , and are not attributed to another disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chronic and episodic forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal hemicrania is further classified depending on the presence of a remission period.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About 80 percent of patients have chronic paroxysmal hemicrania (CPH), in which either no remission occurs within one year, or the remissions last less than one month.",
"     </li>",
"     <li>",
"      The remaining 20 percent of patients have episodic paroxysmal hemicrania (EPH), which is diagnosed when they experience recurrent bouts, each with a duration of more than a week and separated by remissions lasting one month or longer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In EPH, the typical duration of the headache bout ranges from two weeks to four and a half months; remission periods range from 1 to 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/22\">",
"     22",
"    </a>",
"    ]. EPH has been reported to stay episodic for up to 35 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18\">",
"     18",
"    </a>",
"    ]. EPH can evolve into typical CPH and vice versa.",
"   </p>",
"   <p>",
"    Notably in paroxysmal hemicrania, the chronic form dominates the clinical presentation. In contrast, the episodic form prevails in cluster headache. Unlike episodic cluster headache, circannual periodicity does not appear to be a feature of EPH, though three cases with seasonal onset have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/10,11,46\">",
"     10,11,46",
"    </a>",
"    ]. Approximately one-quarter of the CPH cases evolve from EPH, while the remaining three-quarters are chronic from onset [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Indomethacin trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal hemicrania responds in a dramatic and absolute fashion to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , thereby underlining the importance of distinguishing it from cluster headache and",
"    <span class=\"nowrap\">",
"     SUNCT/SUNA,",
"    </span>",
"    which are not responsive to indomethacin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2264?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The existence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    -insensitive paroxysmal hemicrania is controversial, but some patients who have clinical symptoms consistent with paroxysmal hemicrania do not respond to indomethacin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/23,64\">",
"     23,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend a therapeutic trial of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    for patients with active paroxysmal hemicrania who do not have a contraindication. In patients who do not respond to an optimum trial of indomethacin, the diagnosis of paroxysmal hemicrania should be reconsidered.",
"   </p>",
"   <p>",
"    The starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    is 75 mg daily in three divided doses (ie, 25 mg three times a day). The indomethacin dose should be increased to 150 mg daily in three divided doses for 3 to 10 days if there is no response or a partial response to the starting dose after three days. The dose should be further increased to 225 mg daily in three divided doses for 10 days for partial responders if the index of suspicion is high.",
"   </p>",
"   <p>",
"    Complete resolution of the headache is usually prompt, occurring within one to two days of initiating the effective dose, though we have a patient who required 10 days to respond completely to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    (unpublished observation). It is therefore worth considering prolonging the administration of the maximum indomethacin dose to 10 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Indotest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Where available, parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    given intramuscularly has been proposed as a diagnostic test (the \"indotest\") for paroxysmal hemicrania. Two open-label studies of intramuscular indomethacin (100 mg) in six and seven patients reported complete pain relief for a mean of 11.1&plusmn;3.5 hours and 13.4&plusmn;7.7 hours, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indotest has the advantage that the diagnosis can be rapidly established, although it needs further validation at this stage with placebo-controlled trials. Intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    is not available in some countries, including the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Utility of indomethacin trial for trigeminal autonomic cephalalgias",
"    </span>",
"    &nbsp;&mdash;&nbsp;It could be advocated that all patients diagnosed with trigeminal autonomic cephalalgias, who do not have a contraindication to the use of NSAIDs, should have a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    at the start of treatment to detect the indomethacin-sensitive group, at least until a reliable biologic marker becomes available. However, the diagnostic yield will be low, since paroxysmal hemicrania is rare. In addition, this approach will delay appropriate treatment by one to two weeks in patients with cluster headache, unless there is access to the indotest (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Indotest'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The alternative approach is to consider an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    trial only in patients with a high likelihood of having paroxysmal hemicrania. We routinely perform a trial of indomethacin in patients with trigeminal autonomic cephalalgias having more than five attacks daily, or attacks lasting less than 30 minutes, or both. In addition, we consider such a trial in patients with chronic trigeminal autonomic cephalalgias (before committing them to potentially multiple trials of treatment if paroxysmal hemicrania is missed) and patients with cluster headache who are refractory to usual cluster headache treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Laboratory investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned earlier, we suggest a brain MRI scan for all patients with paroxysmal hemicrania to exclude a structural brain lesion, particularly one involving the pituitary fossa [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/61\">",
"     61",
"    </a>",
"    ]. Even cases fitting all criteria for paroxysmal hemicrania, including a complete response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , can have a potential secondary etiology.",
"   </p>",
"   <p>",
"    Further investigations are required when secondary paroxysmal hemicrania is suspected. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Secondary paroxysmal hemicrania'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Secondary paroxysmal hemicrania should be considered when any of the following conditions are present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The clinical picture is atypical",
"     </li>",
"     <li>",
"      There are associated neurologic signs",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      dose is escalating",
"     </li>",
"     <li>",
"      The treatment response is poor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In such cases, in addition to an appropriate neuroimaging study that adequately evaluates the pituitary fossa, we recommend the following investigations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pituitary function tests",
"     </li>",
"     <li>",
"      Blood count, to look for thrombocythemia",
"     </li>",
"     <li>",
"      Vasculitis screen, to look for collagen vascular disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"       \"Classification of and approach to the vasculitides in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lumbar puncture, to look for intracranial hypertension, even in the face of response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      , particularly if the pain becomes bilateral",
"     </li>",
"     <li>",
"      Chest x-ray, to look for a Pancoast tumor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of strictly unilateral, brief but frequent headaches is:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Paroxysmal hemicrania (primary and secondary forms)",
"     </li>",
"     <li>",
"      Cluster headache",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       SUNCT/SUNA",
"      </span>",
"      syndrome",
"     </li>",
"     <li>",
"      Trigeminal neuralgia",
"     </li>",
"     <li>",
"      Primary stabbing headache",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One-third of patients with paroxysmal hemicrania report interictal pain. In such cases, hemicrania continua should be considered in the differential diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Secondary paroxysmal hemicrania",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary (symptomatic) paroxysmal hemicrania is relatively common and can be associated with diverse pathologic processes at various sites, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Following coil embolization of a supraclinoid carotid artery aneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cerebral arteriovenous malformation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/68\">",
"       68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Middle cerebral artery territory infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/68\">",
"       68",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Occipital infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/69\">",
"       69",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pituitary adenoma [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/23,70,71\">",
"       23,70,71",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Frontal lobe tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/72\">",
"       72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Gangliocytoma of the sella turcica [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/73\">",
"       73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cavernous sinus meningioma [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/74\">",
"       74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Petrous ridge meningioma [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intracranial parotid carcinoma metastases [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pancoast tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Tuber cinereum hamartoma [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Miscellaneous",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Collagen vascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/72\">",
"       72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Essential thrombocythemia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/79\">",
"       79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intracranial hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/80\">",
"       80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Maxillary cyst [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ophthalmic herpes zoster [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/81\">",
"       81",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Post-traumatic [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even cases fitting all criteria for paroxysmal hemicrania, including a complete response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , can have a potential secondary etiology. Thus, we suggest neuroimaging for all patients with suspected paroxysmal hemicrania [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cluster headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a considerable overlap in the clinical phenotype of paroxysmal hemicrania and cluster headache; both are strictly unilateral and relatively brief but frequent headaches that occur in association with ipsilateral cranial autonomic features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"     \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paroxysmal hemicrania differs from cluster headache for its female predominance, shorter duration of headaches that are more frequent, and the absolute response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    . However, the utility of these features to distinguish paroxysmal hemicrania from cluster headache is limited by the considerable overlap of these characteristics in the two syndromes.",
"   </p>",
"   <p>",
"    Mistaking paroxysmal hemicrania for cluster headache is problematic since generally treatments for cluster headache are not effective for paroxysmal hemicrania. The possible role of an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    trial in the diagnosis of trigeminal autonomic cephalalgias is discussed above. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Utility of indomethacin trial for trigeminal autonomic cephalalgias'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     SUNCT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) differs from paroxysmal hemicrania differs with regard to attack duration, temporal distribution of attacks, attack triggers, sex preponderance, and response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65541 \" href=\"UTD.htm?41/12/42188\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=see_link\">",
"     \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ophthalmic division trigeminal neuralgia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trigeminal neuralgia attacks involving the first division (ophthalmic or V1) of the trigeminal nerve generally last less than five seconds, with durations longer than 30 seconds being very rare [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/82\">",
"     82",
"    </a>",
"    ]. The attacks are accompanied by sparse or no autonomic features [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/30\">",
"     30",
"    </a>",
"    ]. Ophthalmic division trigeminal neuralgia attacks are typically precipitated by stimuli within the trigeminal innervated distribution. Some patients with paroxysmal hemicrania exhibit precipitation mechanisms acting on the nuchal and cervical areas, but no trigeminal trigger zones have been described. Trigeminal neuralgia typically responds well to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link\">",
"     \"Trigeminal neuralgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Primary stabbing headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary stabbing headache refers to brief, sharp, or jabbing pain in the head that occurs either as a single episode or in brief repeated volleys. The pain is usually over the ophthalmic trigeminal distribution while the face is generally spared. The pain usually lasts a fraction of a second, but can persist for up to one minute and recurs at irregular intervals (hours to days). The attacks commonly subside with the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25545/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=see_link\">",
"     \"Primary stabbing headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These headaches are generally easily distinguishable clinically, as they differ in several respects: in primary stabbing headache the site and radiation of pain often varies between attacks; the attacks are very brief; and cranial autonomic features are absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hemicrania continua",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemicrania continua is a strictly unilateral, continuous headache of mild to moderate intensity, with superimposed exacerbations of moderate to severe intensity that are accompanied by trigeminal autonomic features and migrainous symptoms. The syndrome is exquisitely responsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    . Differentiating hemicrania continua and paroxysmal hemicrania, when the latter has interictal pain, can be particularly problematic. Some clinical features can help.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interictal pain in paroxysmal hemicrania is usually described as mild only, whereas background pain in hemicrania continua is often moderate (although it can be mild)",
"     </li>",
"     <li>",
"      Exacerbations in paroxysmal hemicrania are short-lasting, whereas those in hemicrania continua are longer, often lasting several hours",
"     </li>",
"     <li>",
"      The severity of pain during exacerbations is excruciating in paroxysmal hemicrania, whereas it is often moderate or severe in hemicrania continua",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal hemicrania is one of the trigeminal autonomic cephalalgias, a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal hemicrania is a rare condition with a female predominance. Paroxysmal hemicrania may begin at any age, although onset usually occurs during adulthood. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical phenotype of paroxysmal hemicrania is highly characteristic. Patients typically have unilateral, brief, severe attacks of pain associated with cranial autonomic features that recur several times per day. The headache is strictly unilateral, most often in the ophthalmic trigeminal distribution. The headache usually lasts 2 to 30 minutes, but may go on for up to two hours. Ipsilateral cranial autonomic features, such as lacrimation, conjunctival injection, nasal congestion, or rhinorrhea, frequently accompany the headache; eyelid edema, ptosis, miosis, and facial sweating are less frequent. The mean attack frequency is 11 to 14 daily. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of paroxysmal hemicrania is based upon a compatible clinical history in the setting of a normal neurologic examination (",
"      <a class=\"graphic graphic_table graphicRef58505 \" href=\"UTD.htm?11/2/11308\">",
"       table 2",
"      </a>",
"      ). The diagnosis is confirmed by an optimum therapeutic trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with active paroxysmal hemicrania who do not have contraindication, we recommend a therapeutic trial of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      . Complete resolution of the headache is usually prompt, occurring within one to two days of initiating the effective dose. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Indomethacin trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with suspected paroxysmal hemicrania, we suggest an MRI scan of the brain to exclude a structural brain lesion, particularly one involving the pituitary fossa. When secondary paroxysmal hemicrania is suspected, we recommend a brain MRI (if not already performed) and the following additional investigations (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Laboratory investigations'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pituitary function tests",
"     </li>",
"     <li>",
"      Blood count",
"     </li>",
"     <li>",
"      Vasculitis screen",
"     </li>",
"     <li>",
"      Lumbar puncture",
"     </li>",
"     <li>",
"      Chest x-ray",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The differential diagnosis of strictly unilateral, brief but frequent headaches is (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Differential diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary and secondary forms of paroxysmal hemicrania",
"     </li>",
"     <li>",
"      Cluster headache",
"     </li>",
"     <li>",
"      SUNCT syndrome",
"     </li>",
"     <li>",
"      Trigeminal neuralgia",
"     </li>",
"     <li>",
"      Primary stabbing headache",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/1\">",
"      Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120 ( Pt 1):193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/2\">",
"      Goadsby PJ. Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005; 161:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/3\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/4\">",
"      Sjaastad O, Dale I. Evidence for a new (?), treatable headache entity. Headache 1974; 14:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/5\">",
"      Sjaastad O, Dale I. A new (?) Clinical headache entity \"chronic paroxysmal hemicrania\" 2. Acta Neurol Scand 1976; 54:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/6\">",
"      Kudrow L, Esperanca P, Vijayan N. Episodic paroxysmal hemicrania? Cephalalgia 1987; 7:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/7\">",
"      Blau JN, Engel H. Episodic paroxysmal hemicrania: a further case and review of the literature. J Neurol Neurosurg Psychiatry 1990; 53:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/8\">",
"      Coria F, Claveria LE, Jimenez-Jimenez FJ, de Seijas EV. Episodic paroxysmal hemicrania responsive to calcium channel blockers. J Neurol Neurosurg Psychiatry 1992; 55:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/9\">",
"      Newman LC, Gordon ML, Lipton RB, et al. Episodic paroxysmal hemicrania: two new cases and a literature review. Neurology 1992; 42:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/10\">",
"      Veloso GG, Kaup AO, Peres MF, Zukerman E. Episodic paroxysmal hemicrania with seasonal variation: case report and the EPH-cluster headache continuum hypothesis. Arq Neuropsiquiatr 2001; 59:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/11\">",
"      Siow HC. Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors. Cephalalgia 2004; 24:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/12\">",
"      Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988; 8 Suppl 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/13\">",
"      Rapoport AM, Sheftell FD, Baskin SM. Chronic paroxysmal hemicrania--case report of the second known definite occurrence in a male. Cephalalgia 1981; 1:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/14\">",
"      Tehindrazanarivelo AD, Visy JM, Bousser MG. Ipsilateral cluster headache and chronic paroxysmal hemicrania: two case reports. Cephalalgia 1992; 12:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/15\">",
"      Zidverc-Trajkovic J, Pavlovic AM, Mijajlovic M, et al. Cluster headache and paroxysmal hemicrania: differential diagnosis. Cephalalgia 2005; 25:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/16\">",
"      Joubert J, Powell D, Djikowski J. Chronic paroxysmal hemicrania in a South African black. A case report. Cephalalgia 1987; 7:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/17\">",
"      Chakravarty A, Mukherjee A, Roy D. Trigeminal autonomic cephalgias and variants: clinical profile in Indian patients. Cephalalgia 2004; 24:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/18\">",
"      Antonaci F, Sjaastad O. Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations. Headache 1989; 29:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/19\">",
"      Russell MB. Epidemiology and genetics of cluster headache. Lancet Neurol 2004; 3:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/20\">",
"      Sjaastad O, Bakketeig LS. The rare, unilateral headaches. V&aring;g&aring; study of headache epidemiology. J Headache Pain 2007; 8:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/21\">",
"      Sjaastad O, Bakketeig LS. Cluster headache prevalence. V&aring;g&aring; study of headache epidemiology. Cephalalgia 2003; 23:528.",
"     </a>",
"    </li>",
"    <li>",
"     Newman, LC, Lipton, RB. Paroxysmal hemicranias. In: Headache, Goadsby, PJ, Silberstein SD (Ed), Butterworth-Heinemann, Oxford 1997. p.243.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/23\">",
"      Boes CJ, Dodick DW. Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients. Headache 2002; 42:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/24\">",
"      Cittadini E, Matharu MS, Goadsby PJ. Paroxysmal hemicrania: a prospective clinical study of 31 cases. Brain 2008; 131:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/25\">",
"      de Almeida DB, Cunali PA, Santos HL, et al. Chronic paroxysmal hemicrania in early childhood: case report. Cephalalgia 2004; 24:608.",
"     </a>",
"    </li>",
"    <li>",
"     Russell, D. Paroxysmal hemicrania. In: Cluster Headache &amp; Related Conditions. Olesen J, Goadsby PJ, (Eds), Oxford University Press, Oxford 1999. p.27.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/27\">",
"      Blankenburg M, Hechler T, Dubbel G, et al. Paroxysmal hemicrania in children--symptoms, diagnostic criteria, therapy and outcome. Cephalalgia 2009; 29:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/28\">",
"      Russell D. Chronic paroxysmal hemicrania: severity, duration and time of occurrence of attacks. Cephalalgia 1984; 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/29\">",
"      Irimia P, Cittadini E, Paemeleire K, et al. Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias. Cephalalgia 2008; 28:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/30\">",
"      Goadsby PJ, Matharu MS, Boes CJ. SUNCT syndrome or trigeminal neuralgia with lacrimation. Cephalalgia 2001; 21:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/31\">",
"      Kayed K, Godtlibsen OB, Sjaastad O. Chronic paroxysmal hemicrania IV: \"REM sleep locked\" nocturnal headache attacks. Sleep 1978; 1:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/32\">",
"      Sjaastad O, Apfelbaum R, Caskey W, et al. Chronic paroxysmal hemicrania (CPH). The clinical manifestations. A review. Ups J Med Sci Suppl 1980; 31:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/33\">",
"      Stein HJ, Rogado AZ. Headache rounds. Chronic paroxysmal hemicrania: two new patients. Headache 1980; 20:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/34\">",
"      Pelz M, Merskey H. A case of pre-chronic paroxysmal hemicrania. Cephalalgia 1982; 2:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/35\">",
"      Bogucki A, Szymaska R, Braciak W. Chronic paroxysmal hemicrania: lack of pre-chronic stage. Cephalalgia 1984; 4:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/36\">",
"      Pradalier A, Dry J. [Chronic paroxysmal hemicrania. Treatment with indomethacin and diclofenac]. Therapie 1984; 39:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/37\">",
"      Pareja JA. Chronic paroxysmal hemicrania: dissociation of the pain and autonomic features. Headache 1995; 35:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/38\">",
"      P&ouml;llmann W, Pfaffenrath V. Chronic paroxysmal hemicrania: the first possible bilateral case. Cephalalgia 1986; 6:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/39\">",
"      Mulder LJ, Spierings EL. Non-lateralized pain in a case of chronic paroxysmal hemicrania? Cephalalgia 2004; 24:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/40\">",
"      Bingel U, Weiller C. An unusual indomethacin-sensitive headache: a case of bilateral episodic paroxysmal hemicrania without autonomic symptoms? Cephalalgia 2005; 25:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/41\">",
"      Matharu MS, Goadsby PJ. Bilateral paroxysmal hemicrania or bilateral paroxysmal cephalalgia, another novel indomethacin-responsive primary headache syndrome? Cephalalgia 2005; 25:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/42\">",
"      Boes CJ, Swanson JW, Dodick DW. Chronic paroxysmal hemicrania presenting as otalgia with a sensation of external acoustic meatus obstruction: two cases and a pathophysiologic hypothesis. Headache 1998; 38:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/43\">",
"      Matharu MJ, Goadsby PJ. Post-traumatic chronic paroxysmal hemicrania (CPH) with aura. Neurology 2001; 56:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/44\">",
"      Purdy RA, Dodick DW. Red ear syndrome. Curr Pain Headache Rep 2007; 11:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/45\">",
"      Dodick DW. Extratrigeminal episodic paroxysmal hemicrania. Further clinical evidence of functionally relevant brain stem connections. Headache 1998; 38:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/46\">",
"      Rossi P, Di Lorenzo G, Faroni J, Sauli E. Seasonal, extratrigeminal, episodic paroxysmal hemicrania successfully treated with single suboccipital steroid injections. Eur J Neurol 2005; 12:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/47\">",
"      Hannerz J. Trigeminal neuralgia with chronic paroxysmal hemicrania: the CPH-tic syndrome. Cephalalgia 1993; 13:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/48\">",
"      Caminero AB, Pareja JA, Dobato JL. Chronic paroxysmal hemicrania-tic syndrome. Cephalalgia 1998; 18:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/49\">",
"      Zukerman E, Peres MF, Kaup AO, et al. Chronic paroxysmal hemicrania-tic syndrome. Neurology 2000; 54:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/50\">",
"      Mart&iacute;nez-Salio A, Porta-Etessam J, P&eacute;rez-Mart&iacute;nez D, et al. Case reports: chronic paroxysmal hemicrania-tic syndrome. Headache 2000; 40:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/51\">",
"      Boes CJ, Matharu MS, Goadsby PJ. The paroxysmal hemicrania-tic syndrome. Cephalalgia 2003; 23:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/52\">",
"      Sanahuja J, Vazquez P, Falguera M. Paroxysmal hemicrania-tic syndrome responsive to acetazolamide. Cephalalgia 2005; 25:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/53\">",
"      Jotkowitz S. Chronic paroxysmal hemicrania and cluster. Ann Neurol 1978; 4:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/54\">",
"      Pearce SH, Cox JG, Pearce JM. Chronic paroxysmal hemicrania, episodic cluster headache and classic migraine in one patient. J Neurol Neurosurg Psychiatry 1987; 50:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/55\">",
"      Centonze V, Bassi A, Causarano V, et al. Simultaneous occurrence of ipsilateral cluster headache and chronic paroxysmal hemicrania: a case report. Headache 2000; 40:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/56\">",
"      Cohen AS, Matharu MS, Goadsby PJ. Paroxysmal hemicrania in a family. Cephalalgia 2006; 26:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/57\">",
"      Pareja J, Pareja J. Chronic paroxysmal hemicrania coexisting with migraine. Differential response to pharmacological treatment. Headache 1992; 32:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/58\">",
"      Sjaastad O, Egge K, H&oslash;rven I, et al. Chronic paroxysmal hemicranial: mechanical precipitation of attacks. Headache 1979; 19:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/59\">",
"      Mateo I, Pascual J. Coexistence of chronic paroxysmal hemicrania and benign cough headache. Headache 1999; 39:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/60\">",
"      M&uuml;ller KI, Bekkelund SI. Hemicrania continua changed to chronic paroxysmal hemicrania after treatment with cyclooxygenase-2 inhibitor. Headache 2011; 51:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/61\">",
"      Favier I, van Vliet JA, Roon KI, et al. Trigeminal autonomic cephalgias due to structural lesions: a review of 31 cases. Arch Neurol 2007; 64:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/62\">",
"      Antonaci F, Costa A, Ghirmai S, et al. Parenteral indomethacin (the INDOTEST) in cluster headache. Cephalalgia 2003; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/63\">",
"      Matharu MS, Goadsby PJ. Functional brain imaging in hemicrania continua: implications for nosology and pathophysiology. Curr Pain Headache Rep 2005; 9:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/64\">",
"      Fuad F, Jones NS. Paroxysmal hemicrania and cluster headache: two discrete entities or is there an overlap? Clin Otolaryngol Allied Sci 2002; 27:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/65\">",
"      Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the 'indotest'. Headache 1998; 38:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/66\">",
"      Matharu MS, Cohen AS, Frackowiak RS, Goadsby PJ. Posterior hypothalamic activation in paroxysmal hemicrania. Ann Neurol 2006; 59:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/67\">",
"      Irimia P, Barbosa C, Martinez-Vila E. Paroxysmal hemicrania after carotid aneurysm embolization. Cephalalgia 2005; 25:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/68\">",
"      Newman LC, Herskovitz S, Lipton RB, Solomon S. Chronic paroxysmal headache: two cases with cerebrovascular disease. Headache 1992; 32:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/69\">",
"      Broeske D, Lenn NJ, Cantos E. Chronic paroxysmal hemicrania in a young child: possible relation to ipsilateral occipital infarction. J Child Neurol 1993; 8:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/70\">",
"      Gatzonis S, Mitsikostas DD, Ilias A, et al. Two more secondary headaches mimicking chronic paroxysmal hemicrania. Is this the exception or the rule? Headache 1996; 36:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/71\">",
"      Sarov M, Valade D, Jublanc C, Ducros A. Chronic paroxysmal hemicrania in a patient with a macroprolactinoma. Cephalalgia 2006; 26:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/72\">",
"      Medina JL. Organic headaches mimicking chronic paroxysmal hemicrania. Headache 1992; 32:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/73\">",
"      Vijayan N. Symptomatic chronic paroxysmal hemicrania. Cephalalgia 1992; 12:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/74\">",
"      Sjaastad O, Stovner LJ, Stolt-Nielsen A, et al. CPH and hemicrania continua: requirements of high indomethacin dosages--an ominous sign? Headache 1995; 35:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/75\">",
"      Mariano da Silva H, Benevides-Luz I, Santos AC, et al. Chronic paroxysmal hemicrania as a manifestation of intracranial parotid gland carcinoma metastasis--a case report. Cephalalgia 2004; 24:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/76\">",
"      Mariano, HS, Bigal, ME, Bordini, CA, Speciali, JG. Chronic paroxysmal hemicrania (CPH)-like syndrome as a first manifestation of cerebral metastasis of parotid epidermoid carcinoma: a case report [abstract]. Cephalalgia 1999; 19:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/77\">",
"      Delreux V, Kevers L, Callewaert A. [Paroxysmal hemicrania preceding Pancoast's syndrome]. Rev Neurol (Paris) 1989; 145:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/78\">",
"      Pauri, F, Tilia, G, Cisternino, M, Pierelli, F. Tuber cinereum hamartomas mimicking chronic paroxysmal hemicrania. Ital J Neurol Sci 1993; 14 Suppl 7:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/79\">",
"      MacMillan JC, Nukada H. Chronic paroxysmal hemicrania. N Z Med J 1989; 102:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/80\">",
"      Hannerz J, Jogestrand T. Intracranial hypertension and sumatriptan efficacy in a case of chronic paroxysmal hemicrania which became bilateral. (The mechanism of indomethacin in CPH). Headache 1993; 33:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/81\">",
"      Giacovazzo M, Di Sabato F, Gallo MF, et al. [\"Chronic paroxysmal hemicrania\" following ophthalmic herpes zoster]. Riv Eur Sci Med Farmacol 1992; 14:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/82\">",
"      Sjaastad O, Pareja JA, Zukerman E, et al. Trigeminal neuralgia. Clinical manifestations of first division involvement. Headache 1997; 37:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25545/abstract/83\">",
"      Pareja JA, Kruszewski P, Caminero AB. SUNCT syndrome versus idiopathic stabbing headache (jabs and jolts syndrome). Cephalalgia 1999; 19 Suppl 25:46.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3334 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-CCD5015BA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25545=[""].join("\n");
var outline_f24_60_25545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sex distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Age of onset",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Side, laterality, severity, and character of pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Duration of the individual attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Associated features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Frequency and periodicity of attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atypical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Comorbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chronic and episodic forms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Indomethacin trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Indotest",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Utility of indomethacin trial for trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Laboratory investigations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Secondary paroxysmal hemicrania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cluster headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUNCT syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ophthalmic division trigeminal neuralgia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hemicrania continua",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3334\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3334|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/12/42188\" title=\"table 1\">",
"      Clinical features trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/2/11308\" title=\"table 2\">",
"      Diagnostic criteria paroxysmal hemicrania",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9112?source=related_link\">",
"      Paroxysmal hemicrania: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27174?source=related_link\">",
"      Pathophysiology of the trigeminal autonomic cephalalgias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22101?source=related_link\">",
"      Primary cough headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13714?source=related_link\">",
"      Primary stabbing headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2264?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=related_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_60_25546="Management of infantile hemangiomas";
var content_f24_60_25546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of infantile hemangiomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25546/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25546/contributors\">",
"     Denise W Metry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25546/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25546/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/60/25546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/60/25546/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/60/25546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile hemangiomas are benign tumors of vascular endothelium. They are the most common tumors of childhood. They are characterized by a growth phase and involution phase. Despite their benign and self-limited nature, some hemangiomas can cause complications such as ulceration or life-altering disfigurement. In addition, they may compromise vital organ function, or herald underlying developmental anomalies of the central nervous system or spine. Infants with multiple cutaneous hemangiomas occasionally have symptomatic hemangiomas of the liver, brain, respiratory tract, or gastrointestinal tract. Rarely, visceral hemangiomas can be associated with life-threatening complications.",
"   </p>",
"   <p>",
"    The management of infantile hemangiomas will be discussed below. The epidemiology, pathogenesis, clinical features, complications, and evaluation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5495?source=see_link\">",
"     \"Evaluation and diagnosis of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of hemangioma management include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention or reversal of life-threatening or function-threatening complications (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link&amp;anchor=H15#H15\">",
"       \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\", section on 'Complications'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prevention or minimization of disfigurement from residual skin changes",
"     </li>",
"     <li>",
"      Minimization of psychosocial distress for the patient and family",
"     </li>",
"     <li>",
"      Adequate treatment of ulceration to minimize scarring, bleeding, infection, and pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to the treatment of hemangiomas is individualized based upon the size of the lesion(s), morphology, location, presence or possibility of complications, potential for scarring or disfigurement, the age of the patient, and the rate of growth or involution at the time of evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The potential risk(s) of treatment must be carefully weighed against the potential benefits.",
"   </p>",
"   <p>",
"    Consultation with",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    referral to a pediatric dermatologist, vascular anomalies team, or other knowledgeable specialist, is warranted for children with hemangiomas with actual or potential risk for complications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when therapy is being considered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/3\">",
"     3",
"    </a>",
"    ]. Such children should be referred as early as possible during the early proliferation phase (ie, during the first few months of life).",
"   </p>",
"   <p>",
"    Most hemangiomas are managed with clinical examination(s) and education of the family regarding the natural course, potential complications, treatment indications, and risks, benefits, and expectations of available treatment options. Depending upon the type of lesion and the parents' level of concern, the patient may need to be reevaluated frequently during the proliferative phase, and again before school entry. Serial photographs of the lesion can help to monitor the clinical course.",
"   </p>",
"   <p>",
"    When treatment is indicated, the choice of treatment modality depends upon the above factors as well as the availability of certain modalities and the experience of the treating clinician. The interventions described below may be used singly or in combination. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Systemic pharmacotherapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H30\">",
"     'Local pharmacotherapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H41\">",
"     'Other modalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Education of the family should include information about the natural course, potential complications, treatment indications, and risks, benefits, and expectations of available treatment options for hemangiomas.",
"   </p>",
"   <p>",
"    The family should be provided with realistic expectations about the duration of involution and the possibility of residual changes. Completed involution occurs at an estimated minimum rate of 10 percent per year, so approximately 50 percent of hemangiomas have involuted by age five years, 70 percent by age seven, and 90 percent by age nine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/4\">",
"     4",
"    </a>",
"    ]. It must be emphasized that in many cases, involution does not result in normal-appearing skin. Nearly one-half of children with hemangiomas experience residual changes such as scarring, atrophy, redundant skin, discoloration, and telangiectasias:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of scarring is greatest with large, nodular, superficial hemangiomas, especially those that exhibit a sharp, 'cliff-like' border (",
"      <a class=\"graphic graphic_picture graphicRef61868 \" href=\"UTD.htm?39/31/40434\">",
"       picture 1",
"      </a>",
"      ), or with pedunculated lesions (hemangiomas extending from a small base), which are at risk for leaving residual fibrofatty tissue that may require surgical revision.",
"     </li>",
"     <li>",
"      Large, plaque-like (segmental) or nodular hemangiomas, especially in trauma-prone locations, have a tendency toward ulceration, which invariably leads to scarring.",
"     </li>",
"     <li>",
"      Hemangiomas of the lip (",
"      <a class=\"graphic graphic_picture graphicRef60003 \" href=\"UTD.htm?0/32/512\">",
"       picture 2",
"      </a>",
"      ), nose (\"Cyrano nose\"), and auricle are particularly prone to disfigurement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finally, the family should be provided with anticipatory guidance regarding ways to respond to comments and queries from family members and strangers. Other children, who are usually extremely curious about the hemangioma, are often satisfied to know simply that \"It is a birthmark, it doesn't hurt, and it will get better\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Active nonintervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active nonintervention is the mainstay of therapy for most uncomplicated hemangiomas because hemangiomas involute spontaneously. However, the decision not to pursue medical and surgical therapy is not necessarily a passive intervention since the growth and involution of the hemangioma may need to be monitored, and the psychosocial implications, particularly of facial hemangiomas, anticipated and addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents are commonly subject to inappropriate comments from strangers, including accusations of child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/5\">",
"     5",
"    </a>",
"    ]. Infants and children may be indirectly affected when they sense a parent's embarrassment, fear, or depression. Addressing the psychosocial aspects of care and providing the parents anticipatory guidance, emotional support, and reassurance are essential for the effective management of hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/1,5-7\">",
"     1,5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Indications for intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intervention may be required for lesions with potential to interfere with a vital structure or function. These include, but are not limited to [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesions in the airway, liver, or gastrointestinal tract",
"     </li>",
"     <li>",
"      Lesions in the periorbital region",
"     </li>",
"     <li>",
"      Very large, rapidly growing cutaneous hemangiomas",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, intervention may be indicated for lesions associated with other complications such as ulceration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased risk of scarring or disfigurement. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lesions complicated by ulceration",
"     </li>",
"     <li>",
"      Lesions of the nose, lip, or ear",
"     </li>",
"     <li>",
"      Large, segmental hemangiomas of the face",
"     </li>",
"     <li>",
"      Pedunculated hemangiomas",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Airway hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoids or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    are generally the first line of therapy for children with enlarging airway hemangiomas, although tracheotomy may also be required [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Laser ablation is an occasional second-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7862164\">",
"     'Systemic glucocorticoids'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Propranolol'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     High-output failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with significant hepatic or very large cutaneous hemangiomas may rarely develop high-output heart failure within the first several months of life. Treatment in such cases may include: systemic glucocorticoids;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    or interferon in glucocorticoid-unresponsive, life-threatening cases; hepatic arterial embolization in selected hepatic cases;",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of heart failure (with fluid restriction, diuretics, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    as indicated) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Periorbital hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periorbital hemangiomas should be evaluated by an ophthalmologist experienced with hemangiomas and their treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/13\">",
"     13",
"    </a>",
"    ]. Therapy may be as simple as patching the unaffected eye to ensure that the partially obstructed eye is used. Vision-threatening cases are generally treated systemically with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or glucocorticoids, or less commonly with intralesional glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. Superficial periocular hemangiomas have been successfully treated with topical beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Surgical excision also may be an option for small, localized lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Propranolol'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H57920874\">",
"     'Topical beta blockers'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ulceration",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59920365\">",
"    <span class=\"h3\">",
"     Oral propranolol",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    in addition to meticulous wound care and appropriate analgesia for the treatment of ulcerated hemangiomas that may cause permanent disfigurement; interfere with daily life activities (eg, diaper changes, bathing, feeding, sleeping); or are unresponsive to wound care and pain and infection control. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Propranolol'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    on ulcerated hemangiomas has been reported in several case series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. In two studies, treatment with oral propranolol (2.0 to 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) was associated with a shorter time to pain control and healing (mean time to healing of 4.3 and 8.7 weeks compared with 22.4 weeks in a group of historical controls treated only with supportive measures) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. There are no studies comparing oral propranolol with other systemic therapies for the treatment of ulcerated hemangiomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gentle and meticulous local wound care is the mainstay of ulcer therapy and is particularly important for lesions in locations subject to trauma and infection, such as the perineum (",
"    <a class=\"graphic graphic_picture graphicRef74768 \" href=\"UTD.htm?11/51/12095\">",
"     picture 3",
"    </a>",
"    ). Local wound care reduces pain and helps to prevent secondary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/29\">",
"     29",
"    </a>",
"    ]. Commonly used therapies include topical antibiotics, barrier creams, and non-stick dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/30\">",
"     30",
"    </a>",
"    ]. Corticosteroids (topical, intralesional, or systemic) may also help promote healing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Debridement of crusted wounds with diluted",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    or saline soaks two to three times daily may be helpful, since crusting prevents re-epithelization and favors infection.",
"   </p>",
"   <p>",
"    Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    gel, often used in combination with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    , has proved to be safe and efficacious for ulceration, particularly in intertriginous or moist areas such as the lip and perineum [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/29\">",
"     29",
"    </a>",
"    ]. When clinically indicated, broad-spectrum oral antibiotics are also occasionally used.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/61/30675?source=see_link\">",
"     Becaplermin",
"    </a>",
"    , a synthetic form of platelet-derived growth factor, is approved by the United States Food and Drug Administration for treatment of lower-extremity diabetic neuropathic ulcers. It has been reported to be effective as a second-line topical therapy in the treatment of ulcerated hemangiomas that are refractory to standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/61/30675?source=see_link\">",
"     Becaplermin",
"    </a>",
"    contains a boxed warning about the possible risk of death from cancer in patients who receive repeated treatment with becaplermin. The studies that prompted the warning were performed in adult patients with diabetes. No cases of cancer have been reported in children who were treated with becaplermin for hemangioma ulceration. Additional information regarding becaplermin and the risk of cancer in patients with hemangioma can be obtained from the",
"    <a class=\"external\" href=\"file://onlinelibrary.wiley.com.ezp-prod1.hul.harvard.edu/doi/10.1111/j.1525-1470.2008.00781_3.x/pdf\">",
"     National Organization of Vascular Anomalies",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain associated with ulceration can be severe. Affected infants commonly suffer from sleep disturbance and increased irritability. Use of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    ) or a topical anesthetic agent (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    hydrochloride 2% to 5% ointment) may be warranted. To avoid the risk of lidocaine toxicity, parents should be instructed to apply only a pea-sized amount of lidocaine to the affected area no more than four times per day.",
"   </p>",
"   <p>",
"    EMLA (eutectic mixture of local anesthetics) should be avoided in infants less than three months of age because it contains",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    hydrochloride, which has been associated with infantile methemoglobinemia. Infants younger than three months have low levels of methemoglobin reductase. The risk of methemoglobinemia is increased when EMLA is used concomitantly with other methemoglobinemia-associated drugs (",
"    <a class=\"graphic graphic_table graphicRef51406 \" href=\"UTD.htm?38/28/39372\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=see_link&amp;anchor=H11590848#H11590848\">",
"     \"Genetics and pathogenesis of methemoglobinemia\", section on 'Infants and children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SYSTEMIC PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    and systemic glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) are the first-line agents for the majority of potentially disfiguring or complicated infantile hemangiomas that require intervention.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     Vincristine",
"    </a>",
"    and interferon alpha are alternative systemic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Propranolol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    , a nonselective beta-blocker, inhibits the growth of infantile hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential mechanisms of action for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    include vasoconstriction, decreased expression of vascular endothelial growth factor and basic fibroblast growth factor,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    triggering of apoptosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    to treat heart failure in two young children with infantile hemangiomas was associated with a change in color, softening, and decrease in size of the hemangioma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/35\">",
"     35",
"    </a>",
"    ]. The effects were replicated in an open trial of propranolol in nine children with disfiguring hemangiomas.",
"   </p>",
"   <p>",
"    These favorable results led to the initiation of larger observational studies, all of which demonstrated improvement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/14,36-39\">",
"     14,36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial, 39 children aged 11 weeks to four years with hemangiomas located in sites that could impair function or result in esthetic disfigurement were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or placebo for 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/9\">",
"     9",
"    </a>",
"    ]. Response to therapy was measured by blinded volume estimation at baseline and every four weeks thereafter. In the group assigned to propranolol, the hemangioma involution started after four weeks and continued steadily until the end of the study. After 24 weeks, the tumor volume had decreased by 60 percent in the propranolol and 14 percent in the placebo group, compared to baseline. Side effects were reported more frequently in the propranolol group (68 percent versus 25 percent) and included bronchiolitis, sleep disturbance, and viral or bacterial infections.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    has also been used to treat infantile hemangiomas beyond the proliferative phase. In a multicentric retrospective study, 42 children aged 7 months to 10 years with documented cessation of hemangioma growth were treated with propranolol 1.5 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 1 to 8 months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/40\">",
"     40",
"    </a>",
"    ]. In all children the rate of involution increased with propranolol, compared with the rate of involution during active nonintervention before treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59920646\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    as a first-line treatment for hemangiomas with the potential to impair function or cause permanent disfigurement and for ulcerated hemangiomas if there are no cardiac or neurovascular contraindications, including PHACE syndrome. (See",
"    <a class=\"local\" href=\"#H22222255\">",
"     'Initiation of treatment'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6243743\">",
"     'Dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22222255\">",
"    <span class=\"h3\">",
"     Initiation of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    should be undertaken in consultation with a pediatric dermatologist or other specialist with expertise in the management of pediatric vascular tumors and a clinician with expertise in the use of propranolol in children. In accord with an expert consensus panel, we suggest hospitalization for initiation of oral propranolol in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infants &le;8 weeks of age (corrected for gestational age)",
"     </li>",
"     <li>",
"      Infant of any age with inadequate social support",
"     </li>",
"     <li>",
"      Infants of any age with comorbid conditions affecting the cardiovascular or respiratory system, including symptomatic airway hemangiomas",
"     </li>",
"     <li>",
"      Infants of any age with conditions affecting blood glucose maintenance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pretreatment evaluation (inpatient or outpatient) should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History, with focus on cardiovascular and respiratory abnormalities (eg, poor feeding, dyspnea, tachypnea, diaphoresis, wheezing, heart murmur) and family history of heart block or arrhythmia",
"     </li>",
"     <li>",
"      Physical examination including cardiac and pulmonary assessment and measurement of heart rate and blood pressure (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=see_link\">",
"       \"The pediatric physical examination: General principles and standard measurements\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=see_link&amp;anchor=H2#H2\">",
"       \"The pediatric physical examination: Chest and abdomen\", section on 'Chest'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      ECG, especially in children with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Heart rate lower than normal for age",
"     </li>",
"     <li>",
"      History of arrhythmia or arrhythmia detected during examination",
"     </li>",
"     <li>",
"      Family history of congenital heart disease or maternal history of connective tissue disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6243743\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally start treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    at 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses (0.17 to 0.33",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/41\">",
"     41",
"    </a>",
"    ]. If tolerated, the dose is then gradually increased (ie, in increments of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) over one to two weeks to the target dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses (0.66",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6243753\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the effect of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    peaks at one to three hours after administration, patients should be monitored with measurement of heart rate and blood pressure at one and two hours after the initial dose, after every dose increase &gt;0.5",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    and after the target dose has been reached [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/41\">",
"     41",
"    </a>",
"    ]. Parents should be educated about recognizing signs of hypotension, bradycardia, and hypoglycemia. Early clinical signs of hypoglycemia include sweating, shakiness, tachycardia, anxiety, and hunger, all of which may be masked by beta-blockers",
"    <strong>",
"     except",
"    </strong>",
"    sweating. Thus, sweating is the most reliable early sign of hypoglycemia to watch for. Routine screening of serum glucose is not indicated because the timing of hypoglycemic events is variable and unpredictable and asymptomatic hypoglycemia was not detected in studies that included a random serum glucose as part of routine monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=see_link&amp;anchor=H11#H11\">",
"       \"The pediatric physical examination: General principles and standard measurements\", section on 'Heart rate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=see_link&amp;anchor=H12#H12\">",
"       \"The pediatric physical examination: General principles and standard measurements\", section on 'Blood pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44630?source=see_link&amp;anchor=H21347121#H21347121\">",
"       \"Hypertension in infants between one month and one year of age\", section on 'Blood pressure measurement'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291289\">",
"    <span class=\"h3\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proprandol treatment is contraindicated in infants and children with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiogenic shock",
"     </li>",
"     <li>",
"      Sinus bradycardia",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Greater than first-degree heart block",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Hypersensitivity to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    therapy include hypotension, bradycardia, hyperkalemia bronchospasm, and hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Restless sleep, constipation, and cold extremities have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, children treated with this drug should be closely monitored.",
"   </p>",
"   <p>",
"    To reduce the risk of hypoglycemia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    should be administered during the daytime hours with a feeding shortly after administration and discontinued during periods of illness or poor oral intake [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/41,44\">",
"     41,44",
"    </a>",
"    ]. Patients who may be at increased risk for propranolol-induced hypoglycemia include children under the age of one year (especially low birth weight infants), patients who were previously treated with prolonged courses of systemic glucocorticoids, and patients with high output cardiac failure secondary to a large liver hemangioma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28173364\">",
"    <span class=\"h3\">",
"     Propranolol versus glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and systemic glucocorticoids in the treatment of infantile hemangiomas.",
"   </p>",
"   <p>",
"    Data from a retrospective multicenter study indicate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    is safer and may be more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/46\">",
"     46",
"    </a>",
"    ]. This study compared the outcome in 68 children treated with propranolol (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 3.5 to 14 months) and 42 children treated with oral glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    2 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 2.5 to 8 months). Outcome measures included the percentage of hemangioma clearance assessed by serial photography and clinical examination, occurrence of adverse effects and ulceration, and need for surgical referral after treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clearance of &ge;75 percent of the lesion was achieved in 82 and 29 percent of patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      and glucocorticoid groups, respectively.",
"     </li>",
"     <li>",
"      Adverse effects were reported in 2 of 68 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      (transient hypoglycemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nonspecific skin eruption) and in all patients treated with oral glucocorticoids (cushingoid features, gastroesophageal reflux, and hypertension).",
"     </li>",
"     <li>",
"      Ulceration during treatment occurred in 6 and 26 percent of patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      and glucocorticoid groups, respectively.",
"     </li>",
"     <li>",
"      Surgery after treatment was required in 12 and 29 percent of patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      and glucocorticoid groups, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Use in PHACE syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of severe arterial anomalies may preclude or restrict the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    in patients with PHACE syndrome (MIM 606519) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/47\">",
"     47",
"    </a>",
"    ]. In addition to large facial hemangiomas, patients with this disorder exhibit coarctation of the aorta and abnormalities of the cerebral and cervical vasculature and vessels of the aortic arch. It is known that a small percentage of patients with severe cerebral or cervical anomalies develops acute arterial ischemic stroke, most often during infancy or toddlerhood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus, there is at least theoretical concern that propranolol-induced hypotension and reduced cerebrovascular perfusion in patients with already compromised cerebral vasculature could increase the risk of stroke in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\", section on 'PHACE syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consensus guidelines recommend that infants with PHACE syndrome be thoroughly evaluated with magnetic resonance",
"    <span class=\"nowrap\">",
"     imaging/magnetic",
"    </span>",
"    resonance angiography",
"    <span class=\"nowrap\">",
"     (MRI/MRA)",
"    </span>",
"    of the head and neck and cardiac imaging to include the aortic arch before starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/41\">",
"     41",
"    </a>",
"    ]. MRA findings that confer the highest risk of stroke include severe, long-segment narrowing or non-visualization of major head or neck arteries without adequate",
"    <span class=\"nowrap\">",
"     collateral/compensatory",
"    </span>",
"    circulation, especially in the presence of concomitant cardiac and aortic arch anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risks and benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    treatment for patients with PHACE syndrome who have high-risk MRA features should be discussed in consultation with neurology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiology specialists [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/41\">",
"     41",
"    </a>",
"    ]. If the potential benefits of propranolol treatment are deemed to outweigh the risks, propranolol should be given at the lowest possible dose, with slow upward dosage titration and three times daily dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/41\">",
"     41",
"    </a>",
"    ]. This schedule is aimed at minimizing abrupt changes in systolic blood pressure which are a known risk factor for stroke.",
"   </p>",
"   <p>",
"    In a retrospective study, 32 children with PHACE syndrome were successfully treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    at the average dose of 1.8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/49\">",
"     49",
"    </a>",
"    ]. One patient experienced mild right side hemiparesis and two had soft tissue effects (eg, worsening of ulceration, acrocyanosis, nail dystrophy, small digital infarcts). Although no severe neurologic events were reported in this large case series, the possibility that propranolol augments the potential risk of stroke in this population cannot be ignored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7862164\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7862172\">",
"    <span class=\"h3\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of systemic glucocorticoids on infantile hemangiomas is not fully understood, but a direct inhibitory effect on the production of factors that promote vasculogenesis may play an important role. Hemangioma-derived stem cells are capable of inducing de novo blood vessel formation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/50\">",
"     50",
"    </a>",
"    ]. These cells and one of their products, vascular endothelial growth factor A (VEGF-A), have been identified in proliferating infantile hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study that investigated the effects of glucocorticoids on hemangiomas,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppressed VEGF-A production by hemangioma-derived stem cells in vitro and inhibited vasculogenesis in a murine model of hemangioma that contained these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/51\">",
"     51",
"    </a>",
"    ]. In the absence of dexamethasone, silencing the production of VEGF-A by hemangioma-derived stem cells also led to a reduction of vasculogenesis in the murine model. Taken together, the findings of this study suggest that glucocorticoid-mediated inhibition of VEGF-A production by stem cells in hemangiomas may be at least partially responsible for the efficacy of this therapy.",
"   </p>",
"   <p>",
"    In addition, the suppression of other proangiogenic factors may be involved. In the study described above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    also suppressed urokinase plasminogen activator receptor, monocyte chemoattractant protein 1, interleukin-6, and matrix metalloproteinase in hemangioma-derived stem cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7862179\">",
"    <span class=\"h3\">",
"     Dose and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual starting dose for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    is 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, although some clinicians advocate higher starting doses of up to 5 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. A single morning dose is preferred to minimize adrenal suppression. A response (stabilization &plusmn; regression) is usually seen within the first few weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Treatment is generally continued for several months or more, depending upon the indications for treatment, the response, and the child's age at initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    should be slowly discontinued since abrupt discontinuation or rapid tapering of glucocorticoids while a hemangioma is still in its active growth phase may result in rebound proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7862186\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used during the proliferative phase, systemic glucocorticoids often arrest hemangioma growth and may induce regression. In a meta-analysis that reviewed all case series of more than 5 patients in which hemangiomas were treated with systemic glucocorticoids, 24 original case series were included [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients were given a mean",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    equivalent daily dose of 2.9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for a mean of 1.8 months. The response rate was 84 percent (95% CI 78-89 percent). A dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day was found to be more effective than 2",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety and efficacy of high-dose intravenous glucocorticoids and oral glucocorticoids in the treatment of problematic infantile hemangioma were compared in a small randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/55\">",
"     55",
"    </a>",
"    ]. Infants treated orally had greater reduction in hemangioma size at 3 and 12 months than those who were treated with pulse glucocorticoids, suggesting that oral glucocorticoids should continue as the mainstay of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7862193\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid use for infantile hemangiomas often results in minor, transient side effects, but long-term complications are rare. Short-term effects are more likely to develop with higher doses and courses of six months or longer, and resolve with drug tapering.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common complication is the development of a cushingoid facies, which usually begins within the first one to two months of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Personality changes (eg, depressed mood, agitation, insomnia, restlessness) develop in about one-third of infants, usually during the first two weeks of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Delayed skeletal growth, which may be more readily apparent since a child grows most rapidly during the first year of life, results from a temporary inhibition of collagen synthesis. However, nearly all children catch up to the normal growth curve once therapy has been discontinued, usually by 2 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastric upset occurs in at least 20 percent of infants and can be relieved with histamine 2 (H2) blockers, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      hydrochloride, which many initiate routinely along with glucocorticoids [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serious glucocorticoid complications, such as aseptic necrosis of the femoral head, hypertension, osteoporosis, and cataracts, are extremely rare in children [",
"      <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucocorticoids have immunosuppressive effects and can increase the risk for infections. In an uncontrolled study of 16 infants treated with systemic glucocorticoids for hemangiomas, significant reductions in T and B lymphocyte counts were detected during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/58\">",
"     58",
"    </a>",
"    ]. Glucocorticoids also depress the immune system by reducing neutrophil migration to sites of inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are at least two reports of Pneumocystis carinii pneumonia (PCP, but officially renamed Pneumocystis jirovecii pneumonia) developing in infants treated with glucocorticoids for hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. While the true risk of PCP and the utility of antibiotic prophylaxis in this population is not known, some advocate that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    prophylaxis be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/58\">",
"     58",
"    </a>",
"    ], particularly in infants with airway involvement or other risk factors for PCP [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/59\">",
"     59",
"    </a>",
"    ]. We do not routinely administer PCP prophylaxis to children being treated with systemic glucocorticoids for infantile hemangiomas. However, PCP prophylaxis may be warranted in infants who have other risk factors for PCP (eg, premature infants with significant concomitant medical problems). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Live virus vaccines (eg, measles, mumps, rubella [MMR], varicella, rotavirus), should not be administered while infants are taking supraphysiologic glucocorticoid doses. In addition, because the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    is not administered until children are at least one year of age, infants receiving glucocorticoid therapy should avoid exposure to individuals with varicella infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"     \"Standard immunizations for children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunization for diphtheria and tetanus may not be effective in some patients when administered during systemic glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/58\">",
"     58",
"    </a>",
"    ]. Diphtheria and tetanus titers can be used to confirm protection. In a study of 16 patients with infantile hemangiomas who were immunized against tetanus and diphtheria while taking systemic glucocorticoids, 5 had protective tetanus titers and 13 had protective diphtheria titers three months after the completion of glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/58\">",
"     58",
"    </a>",
"    ]. Additional studies are necessary to determine whether titers for diphtheria and tetanus should be routinely performed after treatment is discontinued.",
"   </p>",
"   <p>",
"    Supraphysiologic doses of glucocorticoids may suppress the hypothalamic-pituitary-adrenal axis. \"Stress doses\" of glucocorticoids may be necessary for infants who require medical or surgical hospitalization while undergoing glucocorticoid therapy for infantile hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Vincristine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     Vincristine",
"    </a>",
"    has been used in the treatment of the Kasabach-Merritt phenomenon associated with the nonhemangioma tumors kaposiform hemangioendothelioma and tufted angioma. In vitro, vincristine induces apoptosis of tumor and endothelial cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H14#H14\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Kasabach Merritt syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    has expanded to include more aggressive hemangiomas. It is used as an alternative therapy for glucocorticoid-unresponsive, life-threatening, or severely life-altering hemangiomas because of the recognition of the potential neurotoxicity of interferon. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Interferon alpha'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     Vincristine",
"    </a>",
"    is generally administered by a central venous catheter. Its administration is commonly overseen by a pediatric",
"    <span class=\"nowrap\">",
"     hematologist/oncologist",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Toxicities of vincristine include peripheral neuropathy, constipation, jaw pain, and rarely, leukopenia and anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Interferon alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alpha, a potent inhibitor of angiogenesis, is used as an alternative therapy for aggressive hemangiomas not responsive to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/2,65-67\">",
"     2,65-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of interferon alpha is 3 million",
"    <span class=\"nowrap\">",
"     units/m2",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/1\">",
"     1",
"    </a>",
"    ]. The interval between administration and response ranges from a few weeks to several months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of interferon alpha was illustrated in a report of 20 neonates and infants with life-threatening or vision-threatening hemangiomas that failed to respond to glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/65\">",
"     65",
"    </a>",
"    ]. The hemangiomas regressed by 50 percent or more in 18 of the patients (90 percent) after an average of 7.8 months of treatment. A subsequent open study of 20 patients with severe hemangiomas refractory to glucocorticoid therapy found similar results; 85 percent of subjects achieved a 50 percent reduction in lesion size after six months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common side effects of interferon alpha that are usually transient include fever, irritability, neutropenia, and liver enzyme abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/52\">",
"     52",
"    </a>",
"    ]. The most concerning side effect of interferon is severe neurotoxicity, including spastic diplegia. In one meta-analysis, authors identified 441 patients with vascular lesions treated with interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/68\">",
"     68",
"    </a>",
"    ]. Eleven (2.5 percent) developed permanent spastic diplegia, and 16 developed (3.6 percent) motor developmental complications that reversed upon discontinuation of therapy. All of the patients were &lt;1 year of age at initiation of therapy. The authors concluded that interferon should only be used in infants &lt;1 year of age for life-threatening vascular tumors that have not responded to other forms of treatment.",
"   </p>",
"   <p>",
"    Infants undergoing treatment with interferon should receive a baseline neurologic evaluation and close neurologic monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/68\">",
"     68",
"    </a>",
"    ]. If at all possible, the drug should be stopped at first sign of neurologic abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     LOCAL PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local pharmacotherapy primarily is used in the treatment of small or superficial infantile hemangiomas, and is not indicated for the treatment of life-threatening lesions. Data on the efficacy of topical therapies, including topical corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    , and a topical beta-blocker are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Intralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional corticosteroid injections (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide 10 to 40",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    are most commonly used for small, localized hemangiomas and for ulceration. However, use of this therapy for larger lesions has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Dose and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual doses should not exceed 3",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    A response usually is noted within two weeks, with continued response over the ensuing six to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/13\">",
"     13",
"    </a>",
"    ]. Serial injections are sometimes needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one retrospective review, 155 hemangiomas of the head and neck were treated with intralesional corticosteroid therapy (three to six injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide (10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    at monthly intervals)) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/69\">",
"     69",
"    </a>",
"    ]. The overall response rate (with response defined as &gt;50 percent reduction in volume) was 85 percent. Response varied according to the type of hemangioma, with 80 percent of superficial, 75 percent of deep, and 60 percent of combined hemangiomas demonstrating response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional therapy should be performed cautiously, particularly for periocular hemangiomas, which should be managed by a specialist, most often an ophthalmologist with knowledge and experience in this area. Rare but serious side effects, including eyelid necrosis, central retinal artery occlusion, and adrenal suppression, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/71-75\">",
"     71-75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of high-potency corticosteroids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate cream) for periocular hemangiomas has been described in case series in the ophthalmology and dermatology literature [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. Topical corticosteroid therapy is probably best for small superficial hemangiomas at risk for ulceration or small periocular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects most commonly include local skin atrophy if inadvertently applied to normal surrounding skin. Adrenal suppression is also a possibility, even with localized use [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57920874\">",
"    <span class=\"h2\">",
"     Topical beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of successful treatment of hemangiomas with systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    led to the investigation of topical beta blocker therapy for the treatment of infantile hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/19,82\">",
"     19,82",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H59920365\">",
"     'Oral propranolol'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Topical beta blockers may be used for the treatment of superficial hemangiomas of minor cosmetic concern as an alternative to topical corticosteroids (see",
"    <a class=\"local\" href=\"#H35\">",
"     'Topical corticosteroids'",
"    </a>",
"    above). Topical beta blockers also may have a role in preventing rebound growth in children who are being tapered off oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a decision is made to use topical beta blockers, we use topical (ophthalmic)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"     timolol",
"    </a>",
"    0.5 percent gel twice per day for 6 to 12 weeks or until stable improvement is achieved. If no response is seen after the first 4 to 6 weeks, treatment should be discontinued.",
"   </p>",
"   <p>",
"    The efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31776?source=see_link\">",
"     timolol",
"    </a>",
"    has been confirmed in several case series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/20,82,84-87\">",
"     20,82,84-87",
"    </a>",
"    ]. In a multicenter retrospective study, 73 children (median age four months) were treated with topical timolol 0.5% gel twice daily for an average of three months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/84\">",
"     84",
"    </a>",
"    ]. In most cases, hemangiomas were superficial and localized to the head and neck. A mean improvement of 45 percent was observed in all but one patient. Favorable response was associated with superficial hemangiomas and treatment duration &gt;3 months.",
"   </p>",
"   <p>",
"    A few case series indicate that topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    also may be beneficial for the treatment of superficial hemangiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In one study, regression or cessation of growth was reported in 33 of 39 children aged &le;6 months after 2 to 16 months of therapy; improvement also was reported in all six children aged &ge;7 months after 2 to 3 months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/89\">",
"     89",
"    </a>",
"    ]. In another study, a good or partial response was observed in 25 of 28 hemangiomas in 25 children after 5 to 59 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    has been investigated as a treatment for infantile hemangiomas. There are no randomized trials available, and results from observational studies are conflicting.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is a topical immune response modifier with antiangiogenic and pro-apoptotic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/90\">",
"     90",
"    </a>",
"    ]. The antiangiogenic properties result from its interaction with toll-like receptor 7 on dendritic cells, which leads to the production of interferon alpha, tumor necrosis factor alpha, interferon gamma, and tissue inhibitor of matrix metalloproteinase [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. The inhibitory effect of imiquimod on vascular tumors was supported by an in vivo mouse study in which application of imiquimod decreased tumor cell proliferation and increased apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and a small case series have reported successful treatment of infantile hemangiomas with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. A retrospective chart review of 18 patients treated with the drug was more effective in patients with superficial hemangiomas than lesions with a deep component [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/97\">",
"     97",
"    </a>",
"    ]. Treatment with imiquimod led to the diminution of all 12 superficial hemangiomas, with a mean percentage decrease in size of 60 percent, including four cases of complete clearance. Mixed hemangiomas and deep hemangiomas exhibited a mean percentage decrease in size of 22 percent and 12 percent, respectively.",
"   </p>",
"   <p>",
"    In contrast, a phase II, open-label study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    for superficial and mixed infantile hemangiomas revealed no changes in lesion area, volume, elevation, depth, blood flow, or vessel density after 16 weeks of treatment. [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/98\">",
"     98",
"    </a>",
"    ] The only benefit of treatment observed was an accelerated reduction of surface erythema noted four months after the end of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    therapy for infantile hemangiomas have included local inflammation, crusting, and secondary staphylococcal infections. Transient fever and a case of epistaxis after application to the nasal side wall have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Until further studies are available, the decision to prescribe",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    should be carefully weighed against active non-intervention and other treatment options for individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     OTHER MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a hemangioma poses primarily cosmetic concerns, therapeutic intervention must be tailored on an individual basis. In addition to systemic, topical, and intralesional medications, therapeutic options include laser therapy and surgery. Cautery, irradiation, and cryotherapy may produce more scarring than untreated lesions and are thus",
"    <strong>",
"     not",
"    </strong>",
"    generally recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Pulsed dye laser",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulsed dye laser (PDL) cannot be expected to affect hemangiomas with deep involvement, since the depth of laser penetration is only 1.2 mm. Currently, the most accepted use of pulsed dye laser in the management of hemangiomas is the treatment of ulceration, postinvolution erythema,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    telangiectasias [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/2\">",
"     2",
"    </a>",
"    ]Which hemangiomas benefit most from laser therapy and what the optimal settings are remain areas of controversy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/100\">",
"     100",
"    </a>",
"    ]. Indications, efficacy and adverse effects of PDL therapy for infantile hemangiomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=see_link&amp;anchor=H12910462#H12910462\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Infantile hemangiomas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Excisional surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision is often reserved for involuted lesions with residual scars or loose skin; pedunculated cutaneous hemangiomas (because of the risk of scarring); small, localized periorbital hemangiomas; and for slowly involuting lesions in cosmetically concerning locations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/52,101\">",
"     52,101",
"    </a>",
"    ]. Excisional surgery may also be considered for large periocular hemangiomas, refractory ulcerated hemangiomas, and nasal-tip hemangiomas, but only if medical therapy is thought to pose a greater risk and the resultant scar is likely to be acceptable. In cases without complication, but for which there is uncertainty about the outcome, the benefits and risks of surgical intervention must be carefully considered, since the surgical scar may be worse than the results of spontaneous involution [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/53,102\">",
"     53,102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a last resort, large visceral (especially hepatic) hemangiomas have been treated with arterial embolization after failure of medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/60/25546/abstract/101\">",
"     101",
"    </a>",
"    ]. The results may be temporary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23873?source=see_link\">",
"       \"Patient information: Hemangioma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of hemangioma management include prevention or reversal of life- or function-threatening complications, prevention or minimization of disfigurement, bleeding, infection, and pain, and minimization of psychosocial distress for the patient and family. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to the treatment and the choice of treatment modality for infantile hemangiomas should be individualized depending upon the size of the lesion(s), location, presence of complications, potential for scarring or disfigurement, the age of the patient, the rate of growth or involution at the time of evaluation, the potential risk(s) and benefits of treatment, the availability of the various modalities, and the experience of the treating clinician. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Consultation with",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      referral to a pediatric dermatologist, vascular anomalies team, or other knowledgeable specialist, is warranted for children with hemangiomas with actual or potential risk for complications",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      when therapy is being considered. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The parents and family of all children with hemangiomas should be educated about the expected clinical course and potential complications of hemangiomas. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest active nonintervention for most uncomplicated hemangiomas (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Active nonintervention requires regular monitoring of the clinical course and attention to the psychosocial implications for the child and family. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Active nonintervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intervention is usually required for lesions that may interfere with a vital structure or function and lesions at increased risk for complications, scarring, or disfigurement. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications for intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with periorbital hemangiomas should be evaluated by an ophthalmologist who is experienced in the treatment of hemangiomas. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Periorbital hemangiomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      in addition to meticulous wound care and appropriate analgesia for the treatment of ulcerated hemangiomas that may cause permanent disfigurement, interfere with daily life activities, or do not respond to wound care measures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Ulceration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest systemic glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      2 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) as the first-line pharmacologic treatment for hemangiomas associated with high-output failure (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'High-output failure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7862164\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      as the first-line agent for the treatment of hemangiomas with the potential to impair function or cause disfigurement (eg, periorbital hemangiomas) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Treatment is started with 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day and then gradually increased to the target dose of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Systemic glucocorticoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      2 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally per day) are an alternative. Combination therapy with oral propranolol and systemic glucocorticoids may be warranted for severe and refractory cases. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Airway hemangiomas'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Periorbital hemangiomas'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Propranolol'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7862164\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       Vincristine",
"      </a>",
"      and interferon alpha are additional alternative agents for aggressive hemangiomas that are unresponsive to systemic glucocorticoids. We prefer vincristine to interferon alpha because of the potential neurotoxicity of interferon. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Vincristine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Interferon alpha'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/1\">",
"      Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997; 37:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/2\">",
"      Frieden IJ. Which hemangiomas to treat--and how? Arch Dermatol 1997; 133:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/3\">",
"      Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122:360.",
"     </a>",
"    </li>",
"    <li>",
"     Garzon M. Infantile hemangiomas. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP, et al (Eds), Elsevier Limited, Spain 2008. p.1565.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/5\">",
"      Tanner JL, Dechert MP, Frieden IJ. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics 1998; 101:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/6\">",
"      Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol 2000; 136:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/7\">",
"      Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999; 341:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/8\">",
"      Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a \"beard\" distribution. J Pediatr 1997; 131:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/9\">",
"      Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128:e259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/10\">",
"      Peridis S, Pilgrim G, Athanasopoulos I, Parpounas K. A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Pediatr Otorhinolaryngol 2011; 75:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/11\">",
"      Rahbar R, Nicollas R, Roger G, et al. The biology and management of subglottic hemangioma: past, present, future. Laryngoscope 2004; 114:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/12\">",
"      Greene AK, Rogers GF, Mulliken JB. Management of parotid hemangioma in 100 children. Plast Reconstr Surg 2004; 113:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/13\">",
"      Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: what every physician should know. Pediatr Dermatol 2004; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/14\">",
"      Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009; 124:e423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/15\">",
"      Taban M, Goldberg RA. Propranolol for orbital hemangioma. Ophthalmology 2010; 117:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/16\">",
"      Fay A, Nguyen J, Jakobiec FA, et al. Propranolol for isolated orbital infantile hemangioma. Arch Ophthalmol 2010; 128:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/17\">",
"      Al Dhaybi R, Superstein R, Milet A, et al. Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children. Ophthalmology 2011; 118:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/18\">",
"      Janmohamed SR, Madern GC, Nieuwenhuis K, et al. Evaluation of intra-lesional corticosteroids in the treatment of peri-ocular haemangioma of infancy: still an alternative besides propranolol. Pediatr Surg Int 2012; 28:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/19\">",
"      Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010; 128:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/20\">",
"      Ni N, Langer P, Wagner R, Guo S. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol 2011; 129:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/21\">",
"      Slaughter K, Sullivan T, Boulton J, et al. Early surgical intervention as definitive treatment for ocular adnexal capillary haemangioma. Clin Experiment Ophthalmol 2003; 31:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/22\">",
"      Schneider D, Lee MS, Harrison AR, Sidman J. Excision of periorbital hemangiomas to correct visual abnormalities. Arch Facial Plast Surg 2011; 13:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/23\">",
"      Frank RC, Cowan BJ, Harrop AR, et al. Visual development in infants: visual complications of periocular haemangiomas. J Plast Reconstr Aesthet Surg 2010; 63:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/24\">",
"      Claude O, Picard A, O'Sullivan N, et al. Use of ultrasonic dissection in the early surgical management of periorbital haemangiomas. J Plast Reconstr Aesthet Surg 2008; 61:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/25\">",
"      Saint-Jean M, L&eacute;aut&eacute;-Labr&egrave;ze C, Mazereeuw-Hautier J, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol 2011; 64:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/26\">",
"      Hermans DJ, van Beynum IM, Schultze Kool LJ, et al. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol 2011; 64:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/27\">",
"      Kim LH, Hogeling M, Wargon O, et al. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg 2011; 46:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/28\">",
"      Hong E, Fischer G. Propranolol for recalcitrant ulcerated hemangioma of infancy. Pediatr Dermatol 2012; 29:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/29\">",
"      Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001; 44:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/30\">",
"      Morelli JG, Tan OT, Yohn JJ, Weston WL. Treatment of ulcerated hemangiomas infancy. Arch Pediatr Adolesc Med 1994; 148:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/31\">",
"      Edgerton MT. The treatment of hemangiomas: with special reference to the role of steroid therapy. Ann Surg 1976; 183:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/32\">",
"      Bartoshesky LE, Bull M, Feingold M. Corticosteroid treatment of cutaneous hemangiomas: how effective? A report on 24 children. Clin Pediatr (Phila) 1978; 17:625, 629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/33\">",
"      Sugarman JL, Mauro TM, Frieden IJ. Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor. Arch Dermatol 2002; 138:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/34\">",
"      Metz BJ, Rubenstein MC, Levy ML, Metry DW. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 2004; 140:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/35\">",
"      L&eacute;aut&eacute;-Labr&egrave;ze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358:2649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/36\">",
"      Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope 2009; 119:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/37\">",
"      Denoyelle F, Leboulanger N, Enjolras O, et al. Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol 2009; 73:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/38\">",
"      Theletsane T, Redfern A, Raynham O, et al. Life-threatening infantile haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol 2009; 23:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/39\">",
"      Truong MT, Chang KW, Berk DR, et al. Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma. J Pediatr 2010; 156:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/40\">",
"      Zvulunov A, McCuaig C, Frieden IJ, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol 2011; 28:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/41\">",
"      Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/42\">",
"      Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2009; 26:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/43\">",
"      de Graaf M, Breur JM, Rapha&euml;l MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol 2011; 65:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/44\">",
"      Holland KE, Frieden IJ, Frommelt PC, et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010; 146:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/45\">",
"      Breur JM, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol 2011; 28:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/46\">",
"      Price CJ, Lattouf C, Baum B, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol 2011; 147:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/47\">",
"      Metry DW, Garzon MC, Drolet BA, et al. PHACE syndrome: current knowledge, future directions. Pediatr Dermatol 2009; 26:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/48\">",
"      Siegel DH, Tefft KA, Kelly T, et al. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke 2012; 43:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/49\">",
"      Metry D, Frieden IJ, Hess C, et al. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol 2013; 30:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/50\">",
"      Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008; 118:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/51\">",
"      Greenberger S, Boscolo E, Adini I, et al. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. N Engl J Med 2010; 362:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/52\">",
"      Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg 2001; 27:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/53\">",
"      Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg 2000; 37:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/54\">",
"      Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 2001; 137:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/55\">",
"      Pope E, Krafchik BR, Macarthur C, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics 2007; 119:e1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/56\">",
"      Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999; 104:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/57\">",
"      Lomenick JP, Backeljauw PF, Lucky AW. Growth, bone mineral accretion, and adrenal function in glucocorticoid-treated infants with hemangiomas-- a retrospective study. Pediatr Dermatol 2006; 23:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/58\">",
"      Kelly ME, Juern AM, Grossman WJ, et al. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol 2010; 146:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/59\">",
"      Aviles R, Boyce TG, Thompson DM. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc 2004; 79:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/60\">",
"      Maronn ML, Corden T, Drolet BA. Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Arch Dermatol 2007; 143:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/61\">",
"      George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol 2004; 140:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/62\">",
"      Perez J, Pardo J, Gomez C. Vincristine--an effective treatment of corticoid-resistant life-threatening infantile hemangiomas. Acta Oncol 2002; 41:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/63\">",
"      Fawcett SL, Grant I, Hall PN, et al. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg 2004; 57:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/64\">",
"      Moore J, Lee M, Garzon M, et al. Effective therapy of a vascular tumor of infancy with vincristine. J Pediatr Surg 2001; 36:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/65\">",
"      Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/66\">",
"      Jim&eacute;nez-Hern&aacute;ndez E, Due&ntilde;as-Gonz&aacute;lez MT, Quintero-Curiel JL, et al. Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. Dermatol Surg 2008; 34:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/67\">",
"      Chao YH, Liang DC, Chen SH, et al. Interferon-alpha for alarming hemangiomas in infants: experience of a single institution. Pediatr Int 2009; 51:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/68\">",
"      Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 2004; 114:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/69\">",
"      Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases. J Pediatr Surg 2000; 35:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/70\">",
"      Buckmiller LM, Francis CL, Glade RS. Intralesional steroid injection for proliferative parotid hemangiomas. Int J Pediatr Otorhinolaryngol 2008; 72:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/71\">",
"      Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 1986; 17:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/72\">",
"      Weiss AH. Adrenal suppression after corticosteroid injection of periocular hemangiomas. Am J Ophthalmol 1989; 107:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/73\">",
"      Glatt HJ, Putterman AM, Van Aalst JJ, Levine MR. Adrenal suppression and growth retardation after injection of periocular capillary hemangioma with corticosteroids. Ophthalmic Surg 1991; 22:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/74\">",
"      Sutula FC, Glover AT. Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma. Ophthalmic Surg 1987; 18:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/75\">",
"      Goyal R, Watts P, Lane CM, et al. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. Ophthalmology 2004; 111:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/76\">",
"      Elsas FJ, Lewis AR. Topical treatment of periocular capillary hemangioma. J Pediatr Ophthalmol Strabismus 1994; 31:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/77\">",
"      Cruz OA, Zarnegar SR, Myers SE. Treatment of periocular capillary hemangioma with topical clobetasol propionate. Ophthalmology 1995; 102:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/78\">",
"      Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 2005; 52:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/79\">",
"      Mills CM, Marks R. Side effects of topical glucocorticoids. Curr Probl Dermatol 1993; 21:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/80\">",
"      Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998; 38:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/81\">",
"      Olsen EA, Cornell RC. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol 1986; 15:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/82\">",
"      Pope E, Chakkittakandiyil A. Topical timolol gel for infantile hemangiomas: a pilot study. Arch Dermatol 2010; 146:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/83\">",
"      Blatt J, Morrell DS, Buck S, et al. &beta;-blockers for infantile hemangiomas: a single-institution experience. Clin Pediatr (Phila) 2011; 50:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/84\">",
"      Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012; 29:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/85\">",
"      Oranje AP, Janmohamed SR, Madern GC, de Laat PC. Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology 2011; 223:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/86\">",
"      Moehrle M, L&eacute;aut&eacute;-Labr&egrave;ze C, Schmidt V, et al. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol 2013; 30:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/87\">",
"      Chambers CB, Katowitz WR, Katowitz JA, Binenbaum G. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. Ophthal Plast Reconstr Surg 2012; 28:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/88\">",
"      Xu G, Lv R, Zhao Z, Huo R. Topical propranolol for treatment of superficial infantile hemangiomas. J Am Acad Dermatol 2012; 67:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/89\">",
"      Kunzi-Rapp K. Topical propranolol therapy for infantile hemangiomas. Pediatr Dermatol 2012; 29:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/90\">",
"      Sch&ouml;n M, Sch&ouml;n MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem 2007; 14:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/91\">",
"      Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol 2003; 139:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/92\">",
"      Sidbury R, Neuschler N, Neuschler E, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003; 121:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/93\">",
"      Martinez MI, Sanchez-Carpintero I, North PE, Mihm MC Jr. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002; 138:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/94\">",
"      Hazen PG, Carney JF, Engstrom CW, et al. Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol 2005; 22:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/95\">",
"      Barry RB, Hughes BR, Cook LJ. Involution of infantile haemangiomas after imiquimod 5% cream. Clin Exp Dermatol 2008; 33:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/96\">",
"      Welsh O, Olazar&aacute;n Z, G&oacute;mez M, et al. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 2004; 51:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/97\">",
"      Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol 2007; 56:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/98\">",
"      McCuaig CC, Dubois J, Powell J, et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol 2009; 26:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/99\">",
"      Czernik A, Bystryn JC. Does imiquimod work in infantile hemangiomas? J Am Acad Dermatol 2007; 57:535; author reply 536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/100\">",
"      Stier MF, Glick SA, Hirsch RJ. Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas. J Am Acad Dermatol 2008; 58:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/101\">",
"      Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol 1993; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/60/25546/abstract/102\">",
"      McHeik JN, Renauld V, Duport G, et al. Surgical treatment of haemangioma in infants. Br J Plast Surg 2005; 58:1067.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5792 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25546=[""].join("\n");
var outline_f24_60_25546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H47\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Active nonintervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Indications for intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Airway hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      High-output failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Periorbital hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ulceration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59920365\">",
"      - Oral propranolol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Wound care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SYSTEMIC PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Propranolol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59920646\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22222255\">",
"      - Initiation of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6243743\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6243753\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H291289\">",
"      - Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28173364\">",
"      - Propranolol versus glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Use in PHACE syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7862164\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7862172\">",
"      - Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7862179\">",
"      - Dose and duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7862186\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7862193\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Vincristine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Interferon alpha",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      LOCAL PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Intralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Dose and duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57920874\">",
"      Topical beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      OTHER MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Pulsed dye laser",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Excisional surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Embolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5792\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5792|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/31/40434\" title=\"picture 1\">",
"      Hemangioma sharp margins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/32/512\" title=\"picture 2\">",
"      Lip hemangioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/51/12095\" title=\"picture 3\">",
"      Ulcerated hemangioma perineum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5792|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/28/39372\" title=\"table 1\">",
"      Agents causing methemoglobinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5495?source=related_link\">",
"      Evaluation and diagnosis of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=related_link\">",
"      Genetics and pathogenesis of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44630?source=related_link\">",
"      Hypertension in infants between one month and one year of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/47/17146?source=related_link\">",
"      Laser and light therapy for cutaneous vascular lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23873?source=related_link\">",
"      Patient information: Hemangioma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=related_link\">",
"      The pediatric physical examination: Chest and abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=related_link\">",
"      The pediatric physical examination: General principles and standard measurements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_60_25547="Issues urin div selection";
var content_f24_60_25547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Issues affecting urinary diversion selection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cancer control",
"       </td>",
"       <td class=\"subtitle1\">",
"        General health",
"       </td>",
"       <td class=\"subtitle1\">",
"        Technical",
"       </td>",
"       <td class=\"subtitle1\">",
"        Quality of life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of local recurrence",
"       </td>",
"       <td>",
"        Age",
"       </td>",
"       <td>",
"        Functioning urethra",
"       </td>",
"       <td>",
"        Compliance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous pelvic radiation",
"       </td>",
"       <td>",
"        Previous surgeries",
"       </td>",
"       <td>",
"        Tumor location",
"       </td>",
"       <td>",
"        Sexual function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Need for adjuvant therapy",
"       </td>",
"       <td>",
"        Renal/hepatic function",
"       </td>",
"       <td>",
"        Ability to catheterize",
"       </td>",
"       <td>",
"        Body image",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secondary malignancies",
"       </td>",
"       <td>",
"        Medical comorbidities",
"       </td>",
"       <td>",
"        Mesentery length",
"       </td>",
"       <td>",
"        Urinary function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Urethral or bladder neck involvement",
"       </td>",
"       <td>",
"        Status of gastrointestinal tract",
"       </td>",
"       <td>",
"        Bowel condition",
"       </td>",
"       <td>",
"        Family support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Body habitus",
"       </td>",
"       <td>",
"        Operative time",
"       </td>",
"       <td>",
"        Daily maintenance",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25547=[""].join("\n");
var outline_f24_60_25547=null;
var title_f24_60_25548="BAL drug induced lung disease";
var content_f24_60_25548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic value of bronchoalveolar lavage in drug-induced lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Typical findings in BAL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical findings in BAL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Cytotoxic reactions",
"       </td>",
"       <td>",
"        Atypical cells (cytomegaly, cytoplasmic eosinophilia, bizarre cell shape,&nbsp;nuclear&nbsp;hyperchromasia, prominent nucleoli, multinucleation)",
"       </td>",
"       <td rowspan=\"3\">",
"        Chemotherapeutic agents: bleomycin, methotrexate, nitrosoureas, busulfan, cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased eosinophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extracellular lipoproteinaceous debris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Pulmonary hemorrhage",
"       </td>",
"       <td>",
"        Hemosiderin-laden alveolar macrophages",
"       </td>",
"       <td rowspan=\"2\">",
"        D-penicillamine, mineral oil, amphotericin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red blood cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Lymphocytic alveolitis",
"       </td>",
"       <td>",
"        40 to 50 percent lymphocytes",
"       </td>",
"       <td rowspan=\"2\">",
"        Methotrexate, nitrofurantoin, azathioprine, sulfasalazine, cyclophosphamide, amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased CD8+ cells suggestive of hypersensitivity reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased CD4+ to CD8+ ratio",
"       </td>",
"       <td>",
"        BCG therapy, acebutolol, gold salts, propranolol, busulfan, nilutamide, bleomycin, flecainide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutrophilic alveolitis",
"       </td>",
"       <td>",
"        Increased neutrophils",
"       </td>",
"       <td>",
"        Bleomycin, busulfan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilic alveolitis",
"       </td>",
"       <td>",
"        Allergic \"eosinophilic\" reactions",
"       </td>",
"       <td>",
"        Nitrofurantoin, penicillin, sulfasalazine, ampicillin, tetracycline, bleomycin, clotrimazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipoid pneumonia",
"       </td>",
"       <td>",
"        Alveolar macrophages contain large&nbsp;empty vacuoles stained by&nbsp;Oil-Red-O",
"       </td>",
"       <td>",
"        Mineral oil nose-drops or laxatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Thesaurismosis",
"       </td>",
"       <td rowspan=\"2\">",
"        Accumulation of numerous large lamellar inclusions mainly in alveolar macrophages",
"       </td>",
"       <td>",
"        Amiodarone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potentially all amphiphilic drugs",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BAL: bronchoalveolar lavage.",
"    </div>",
"    <div class=\"reference\">",
"     Data from King TE, Jr. Interstitial Lung Disease. In: Feinsilver SH, Fein AM. (Eds), Textbook of Bronchoscopy, Williams &amp; Wilkins, Baltimore, 1995, p. 185-220.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25548=[""].join("\n");
var outline_f24_60_25548=null;
var title_f24_60_25549="Thallium defects and outcome";
var content_f24_60_25549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thallium imaging predicts outcome in patients with chest pain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a group of 158 patients admitted for chest pain in whom no myocardial infarction was diagnosed, a transient defect on thallium imaging, alone or with exercise testing, was identified in 29. These patients had a greater likelihood of a cardiac event during follow-up.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Madsen JK, Stubgaard M, Utal HE, et al. Br Heart J 1988; 59:184.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25549=[""].join("\n");
var outline_f24_60_25549=null;
var title_f24_60_25550="Megakaryocyte development";
var content_f24_60_25550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Origin and development of megakaryocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 392px; background-image: url(data:image/gif;base64,R0lGODlhjgGIAdUAAP///8zMmQAAAICAgEBAQGZmTMDAwKCgoCAgIBAQELCwsH9/X1BQUODg4GBgYPDw8DAwMNDQ0HBwcBkZE5CQkIyMaT8/L7+/j1lZQgwMCXJyVpmZcqWlfCYmHExMOT8/P+/v7x8fH29vbw8PDzMzJt/f35+fn7Kyhb+/v19fX6+vr4+Pj09PT8/Pzy8vLwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACOAYgBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wLsGwwZDBBJNBwQRZREEB0fO0MHUfwLXAgnMAgRNBgMNT9xQAwLFDQPFRgYCA9XvfNcAFAIMAOPf4fnfEQfD4AAGHKBAwB2ABxIIOGB2QAACgAYYHHsQcKDCBw0ICHBwAF2xiAQIUADAziCTBg4SXEvgIBy8l2Hkses2rlwxm+VUDrB5L4EE/wYCRkJIMGBoAwnZlimoh9TeNQgINkaICkFCyYAOBmj0186bSmwr1cEcu+VaUQHQapoLaK6cAiE8xz3gFkEAsqUjxwEAujPqvW5zu/G8+oACAwjtri5p8BXsSpdkI1u5FnKa2ptt17Itppfb1at6Ne7c+VfIZZJdh1Kgl67rEgeOHTuQTJuKPCLj6EEYEPWb5rgQDMAemQBBRAHbjDegx8CAgtmdBScGbRxpa5NJGsfOVrs7lNtD5GqEANS3urgJVCIDEAExgmnlkAeMWq906QZRm3dtyC2xayXbOebdgGbolUeAYBGooBgG4qFdbAksKOEmsCE424QYWsJYgAlAlv/hh2QoE4E0ZxjwYDZigYhhg1/YpJgZKH3FkocqeqeARA4Y0NBD4SgjkhAHDKDARA4sU0RhIY2EkkLMuPhfjVCK0RADA1CJVALLIPVTUABohEBUWDpUhEYSSNBhArult9mLUbbphW4CmdYNAMXtNI5GqLmD5xB1XbjcRlplNsyTbhaqRaB22efQaNDgedWeQrxYTlY7oWMOm4ZmWgUFVk15j3J86ainAHl2SSoR6SmgAAR1QaCAARJE4CR2mtYahQL0MUBRfBE8kFI2o5YKqRARADXOqk9ZOiitZpBm67OAOAvttHtIS+21dliL7bZxaMvtt2x4C+64Z4hL7rlimIv/7rpb0LcSu/B2UeE19sRrLxb8XTPSvfxS0QBYzPQrcBSIiTnwwU4gtRHCDC+xFFoNR4zENTRKLDEBEFis8RADrLexxRG89fHIJJds8skop6zyyiy37PIu6ChA0cvwRqBSVQpUTDO3NoOFAEc67zxtz44hIDS4RGMzzdHcNlDwNSIzze0DTycq9dQQHEPvzFdfixEAB9zMddfY9lwv2X4MM3MEBgTdxHICUcQ2MS7JKuQfPXuM9h76AvAvoU/keydY7swL+BgxrtSSE/xFvfeBYipskI/7FkslQET8m0AxsppKwTANNARBOAos/UQ5zHoVggkoXBPC5glnM/bjdjgk/4ACxXWlJVAUMEaURinOY7UxgIIDlONSeBoFYymER2oKHTbxQFSp0y4HNwykhzqdD5VTEMQ4YeMbrRqJD7wV7GQchQMhgBfehUywI4Db1rvBzVISbL/oTkGuZVMDxHhAQ+bkN1OJBTYmoR8S5nIqKCTABNeAoABGYIKePEE09atdNwzwgO2FKkhLac75ihCVgkjEgEP4W1Z2M4XeROE2I3BM656wlAhlkA4G2p6vVEIUAFwJMcHzm7EQMJIRRqpgwZkCbPTWhNvEZoZPiArybuiHzyFrdmioYRQeaBpsjAAAJrBh7OBHxT/Qx1VviIrpmFChe1yDgtcgY/wMVsZZlP/DaE/YkPN6okAjXAOLdWzFA1SyxiWYaHWtE8DrgsgEIwYSFjkBZBISl43FSQEohXxkKxBzNjRsT5OxqMvwynU4UK6CP5k0ZYYkp8ooVUhXrawRfxAwxVhKaCqUKUZBJGlL2nQQG/RJQCp7SRtKArOWxPSlscBCAEYmMzJVA4sln0mbrIXkmth0JjW3yc1uSkxd3iQLOMMJk3GSEx7mPGc10qnOYLCznb94Jzx34S7uzPMlhuvkPakhuH3tsxp/u0bA/lmNguGRoNVQmBwR+ouHDZOhu6AYRKuBsYmuk4kW7UXIMsrRjnr0oyANqUjrIEAKDHSksriRACxggQwkgAH/B+AlSuUgQEa14QEMyMACLhCAnnJAAxaox2iQOVM1CBAoFiiAUidASzWYyAI87alUe3qBBSi1ABmAZVHZcACk7nSqAdAAxNDAAA2A9axTvYAFhLnVNBgAARP4KloDsICxlmEuUZ0rWivA1Iee6wD5498ZgjQa/sk0C4QtLFGxgIAC6HWqFcjqYbVAAQs89rELYOpix9JBdz1ksskTAAau2tcx4GoCV71qUBmwWSq8FbWpxYBd0tGFA0zgsmldqza10JAK4PaxYvUrPKaSAQxs4LgYyAACToqFpSwArJlt6hcaYla0XkCsrZVCY/daAA8cVAsIeC5kUyveqWrgu15w/+5cK5DaApT3rHUVLjUG2YG8UrUDCZDpS03ahAFgYK7YdcJ+mXuEhpTXqgXwrVQxUL0iDJgJFLitVBGs4ABMwJ9IePASbAvd2ExgA2CdgHzpxAD+OsG/c62rhyvc4ewCwwETsK9ULzCBheIGmEBLwgAcO1cGO8FnOT6CBP4bgA1MACwVLkCDb3yNn3XkCEtRsJGR3NMK3A5AOH7yEcI7VRV7GLroTQKQtaxjHoPVyghi8VR9TJsEiHcBGRCATnu6ABsWtrABwpkRdkznOM85AEre853ttB09E4HPgHaMhAFNq0ETOjaGhguREw2WRbOZY3gutAQcx+E1I+i9Fk7lnf/zvGkkIBqsBUCQAMyM6iVXQwAgDkCcr5GBnm7gVI6OT2wKQmBEz1rOPQ10EXIdIF4Pm8epdox4hY3pQRd7ACdlQHmTDZY3o3fU2zH2ECTAakpvR80iNnWmdw1tU3c72Ko+d7BdTQ1Y99Qxtm7gEcAS6SMgGt6M/jE26n3sKscG2ex241NKbQS8ShXNVO5puCe2b4LvudsIVzaY9T3w1p56qtTejrrz3Wbx/rrWdBXjloO8BBTLGhsgv/QSnNzHU7M3tbFmthJYroQDkODMqWWxzElIciR0erztVTPHmUDzE6t7A7LdjnHnaoER/wLGPIWznJ9LYxtTQb1Sn3NdXQz/hZ/rVeVXWMpoQY1WDwSc6GT/7c65cHGcB12vFxAAaIFBXxlfAL9zZ5xo2ytbp0cBAR5IMHwLIFuuN0EBfYmrjOnM1N0GbtG/XfDZp2DyyGNWn5EhrnGRq1wCN9fRho/CN5AyWtJ2L/RdR2p7S9uu6lp+62FYiustj9aFd6ezwBxA3vuA+ML6/Qo19X16967UtAegqoS3KxhOa/zIn3dCfQRR7xPf3gKsdieop8IB4Cr032IAdm1FQ2IZtXsu0GP2uD1BB0YX/k+c9qoa4MBcN6CBDGC0/ZxIbPYykFSleqADAgABDpB9+FcJEUABo/E5BbiADNiAKCMrvUMsAfMA/56XBeowIkJAgWFQGOXGHhNYgVdwUjUVDg/AQcRSfkpgNy4BNxNoguyBglgAN0XQKwfhgjRIIKwVNhRBANFjAATEBbAhBDyoDz/IBdNzAKuiSz1YhFgQAQmRQhDgD/rAEkLoeFDAWrgSDhKAhMZBElTYJVbYBUOiKkTQEB/xhc00IWlYELPhg2+CFEI4AG3IhFpgAOpDGmxIEnRoBQdQJEPAEUTggwQQDmnYBaxyaO4giIQYhlyAADTSHmmoiGAoIYO0iIPohlzQh/dQhZe4h1kQEkNiiQDkiVWAiXSSEIvjg8IxiVsgHOQDDao4G4VoBlNRJLrHHgTwAJHYTLLIiP/4ZBDNJBymmAXOQBGnEow5QopWgFMKIAGHiIzDWIcEJB/KoIddkhG++DarAhnVaI2DOItlYIfhkBW6yAy7eI3g6B0OAD9r2I2HYk13okvu2AWcIgQ3MonPoIxTYIoNRCpuKBzpmAXOcgAQMDP/WCTZiAWYqIoIEBJowjYbhJAKso5EEIkNCQbH+BEXOV1zQgG9SBIbyQWmCFMkkTGYSABdmAUN4BLPADYFOQQnmZJnED0dU5EfMScomZDAMBOVwYohgZFVKIT6WAXOSACwVIg/yQXOiCXMoIshwQwLqRkxmDVVYRrWhAxRqZMhmDVaFZRZ6YBgGZZiOZZkSQnydCj/k8d2aakGZ0lFbYkFbwmXa5kGcVk/dVkFd4mXc+lJe5lBeUl5fXkFf5kugfk49SRyYnCYZ6CYdcCYtpRPZgCZkQkWmAcHkmlL/WQGmamZYIFhcrCZthRQ8lEGogmCXlCadoCaxGRQaMCardlkeOCaxKRQaECbtRlHeGCbxORQWXQNv9dcvokHvPlMEoUGxWmc8wM50RdIFZUGzemc6oMHz5lMNUmX90cG1YkH2ZlMG5UG3emdBEiL4VmW5Fme5nme6HkvJWWa6SkJKsVSLgVTMNiegoBTOpVXP7Vav0mfGxZTcYA7UDVXVcV6/Kl9ibda43kFGTEB3QdfTCV8BcoE/9sHW+J1XbOVoFHwSwWweJiVWgQaoUPQe3BlfOwlW4ElWF8gQAhAAidAeynWeCAqBPQwdr/1cqa3E1p5BMdhAQ3qolKlAfnFUdM3ACYmktzno9DVXWE2BYOkARyKpGBlAZW5T/aZWi2lYYy1cVBqe1XAAJYFpbh1ARmAobEEoIuXn/FZpMkDeWCKcYUJAAqQAU/apl02pUcTfL43n0lgYLiFpi/1m1xGp6h2nVHUfIJKVXJHNu9ZfaulplXAp7T3U5r1BBF2qGd2ZdrHppZ6Vk3XNdT1pFV1pay1KQJgqJcVXIcnAD3aphhAqEwgbZuKWUtqCgBEDKkAqX2aar95Wv+r+luwV3KTtl7VJ3iXZWXZZ3C4ZaNvF3k1lqOXoGvy9onRSgi4Gnm/qnfoV2XtZaoBAHZCpqV09Wm4VQB2WnNfelle9m2RtwEk8KaVMBORIiQMoCtaAR9B8gyWQxEg8SNvNR0QAQ4eUTp+UyQLQQfVqqzN93xOoF7wtR0M+lgFEJBEEGV6FXHq+lgcgJhOAKvFqmoCoKl6tXamAK9sgSbZMBTJ+RQqgQCIMRtyGCgHEDbc0D+YMSgqMYhoMgBq8pml2mUrNldcqgQD4AFola6x0aPsumSVh1ZJhyDg2lMZwJ4FJwBzumAeKwDZmmKzSgokGxfSwRlfWxqFcRhdsSf/POEk60EPWeFIbVCtRptwreYEgRpi6fZY3koEZaVXb/tvuGUBnimh51qxV3sNvSpVQTuyeuG1m1EaiqsarGEqcOE/l+IakzIayzkGBIB+Tcu3ZyWyRuB1E+axWmqsSpAA8pdiV/u0AdCp5KC6e6txzLqfl/AnSaS4trsW4+AQsFK2t3OAAcgbk2sQrfIqsQIHyCpVGecY6na3RjC3kCW6enVhKQhyeuuxvRp35dd2QDu4qktXWysK0Lq4pzG+3cAfGIQ7QaGLAVgeL4IsAXi5YXAAgetvAXJupLthIFtlmwsWS1e03zsP81u0HqZUhasB5WpuNTq4hRtqL6O9AVAB/5sLW7G2Zq46BPJbrNW3qszLMd2LsK+Hqa0beex1ZNfQf1e1wAvwvyXjwNrqXtWbXccrqNeKwLHqs/tJAURLewsgVz7Kui4DujqsfEvAsTIsxPbWvT6qVglAgAbQATX8WNi7M9vlohbqd0CMpPHVX0hMe5HVlVMgAE+sVwZMGyRyCK9lfAhmpfWAelMMpVXMOPkLpll8BRAwwWG8YOAXGZhSBiyCWHBFwC/3oHfmn/s4onCXxu2FoFDgvHQ6x1fgAFkbq+rHfq4gEPWar0CSJBloi7TlI6N6FYjHNhLxIxUhK7LyEeV2I6RMEgT7DdAQMzsCEJRDLEVCklEQJAqTP/+yu2GG3GXX52iE3HVx7KKOfAUH4MR3/MD2Fwsq6xAt60N2wTsAgBgSgEB7kT9RAUD+4bJrCzHZQDH1ARQNEEJaghq7URAIECH0AFhJ4YTRHBT/shsOcMA1t8uB88dL9R56mgQIEMlBbM9HYrp3/H1kmgnkyz120kwLcxXogJKTayYvObaI4Q4BSDz/Yg9AQRFDsRfJ6TdusdH2USfeUxcIIAEUsM+DZVPL17NJbFV9Jy85LMnrB7+jcND7IxCf0Q6MEYWwYbPpodEJsBpdYSCic2V7gifDEs9W0xndEydDcjOkUK0Cmsa/XNBEEAFyuqknAGcVrAoH/UG6p7vWwQ7/IvTQzPEpu0vRBDRI9sQaISQ8OYKHAmUaoJIYQSIcr7KzoyDVvixUhjUGEODPlod0+DWqtXDQOwQsYHOzXQEbJrssnmO+Q/2DS7RtKqFVwLvEYFPRkYsciU0UTvMUUqsJDTF2UTWg+pwGDEvFC9BSVeGsteAPx2HViAG/SAHQo9B7SKWfbcvS3MWo9UBmkVEhD7EFdTGUqBKkvSBAwdwGZtqwJ0p+MXoIVRpbRjzdizCk2Ifd3N3d3v3dYjmYUSDe4+2uhLlN5H065i0F6e0F7S01780E8S3f6w0G8y00961j9U0O++3e/Q3f/03fa5DfcvlMjjkGB47gYKGxcJDg/6p0mWMA4RFOmXYg4aoEmmOA4RnemXag4aqkmmQA4iEOMKlJ4qsJm2cgm2ag4nTA4rGkm2UA4zGOm3cg42UanGcwnDmO43ag48R0nAXS0chJ00NOTdNpBkeO5NF5B0luS9vZLF3dIlHeBk/eS995BleO5Vb9BVkO3l7+5WAe5mI+CTGL0mO+BoS1NKelyGfOB+9XAA+KFNX1xm2OB/b5XhTWYbhd5+mVAAFqrdfN51zl25YXWVMu6FJC6LQ3yUSO6Flgnwtst3ns6GXw3DKs3JS+4dxKe1Ka6XC65wWm6IIqpqBOn0sxqVyw2rFqZaXeTojX6nJrVnDmxVfQz8lczP8oJXYwii+DjEWVSlVrRaZXHKt1ddJFZXJAus+vlcjBbcGqqueMtel0WgG/vN33pN2FdGqdTgVNal3R1TGiHq72POxJHKZp/NLwJHYemtpCwG0zNqZU4KXoSsDVu4VUAMmHyl4+iuvhtLR0dn1IoXOHXoZZLagjzO5PUMdYXGEcUFxYDMLkxMLIR6wHN1t/vWHPTuyr5YtgvO8fe1/XIO1gNcZ3On53VtDu7qPKuvF7Gu6Hel2YrgRN7PEhv7pwa3lR/DKIt0wIAtDsHOmXdQEFMKuqHsbbvgQ47KIRh1qKhqQ+zDIPM7iBbki8gVpA/1uHCwC2nsxUBe8lt8Xo5rH/Io+8Ac4u9TS4vzkAJDD2lrd25H5WGvBmbJ/C8g323Xq1Bd/2ZY8u9CD1YDHwAWH3ev9wlucBpapigl17fsXCqDu4AXxZnlsyguP3yXI6YL/Dkbd2jH9WAKhoQL8AB7z5U4V0lD/2kQ8KakMsbQMKUU/5C+5iou+zLp9WXn9oW5xmkZfzNDyurj/78EXPndA3f1M9wyIJZ9/7PC60SBxxpadUaHX0tv9Y9Cd/t1a/lvf0hK92yC/tul8KsMlK+zoS/ZoO+UAS4MAP/kASEiEBZp4GfY/8sfG32a9XG6BUJBAgZFcBMc/BEAsEAkGmIzQeLZzAktlsLhAA6ZQ6KDix/8zCkdvlLrJZy4FaNp/RafWa3XaXBQiBIiEfAAaOAUFwOCQECA4GBAzwCgkBBxQEGCQa3yIlIw+8LC+5EBTUrMKYMDDBsAoEzzo9NzC5Miw0lDwDJsjQBjBgm7ZULytul6AmgYOFh6kCGRISCO8eKBggBO74pAgNqQk3ARigB+SIvSl1w72wzxBEwxYwMy6yNgomEAypzGE5xAUwCvQ12NGjzh4k4NUrQK57R64QnEDhW0OH3wIxkqAMAIQEFChAAyDtUDVEhaTwGTDyzkOTVCodPCgBDYUJsCrosgCrwD8pB17eEpeTYKxZZRjM7GlQpYCEvWL+PLmUqZlAAAw8oP8Yx8CjaHMiZITA7aO8jAwMKHDQ1OSjovfITWE0MAzRXbBkTTkFV9zRXgVKUlGwrmfBswImbOibLi1Zww+fTtOYUiQAOgIoPOADQZsBanLlQDr8jdDfcHmn4LwFSte5LHjl2rpF4t4EtjRBS2Fg+u7fDH2XYIi9mXdv378Peda1GwA9dOF4ts27drTK12HiUnkgoN9Qz4L7oga+nXv3hp2FYyIuOku6cBpGg3Z5y60uu1k02AwtNLtn1UOJe9e/n3+V8KryQ+C9JSqYIBzsjisMAfQ8aU+VAZ+Yw4y5rPurA9y060/DDb0D7z8vlKLCAAQCy6IIVTy5QIM+zGCuLef/PEnKFAhpEu6EvjxgiMMdiYmgFB7XYORDL+QzJbklLtDlQiwqsKCRwqaQgAQEnXDwEtqauCCDEEM7spcNMvAMS086kAfIMyMxQKPfEhsmpSGP4NIM45gwDxMPmITsATUMIIDGDSwIszRYLGBADTp7usDJojCgUic0uRtgEEEiYICBPQE4gAACdHzAAQJGMkRTAhjYRM07FBggAgMY2FRHSSNQdQBDLIvAsVZ1hOpTBywjo4FFKkFggAYydVWKCD5lQE6U4DSiSFreA1RQLyxwtCCW2CDPEw6sFGJMJipIANOW6MONtHsY7GkDCCDdTgiL4nhmrEck0IahZyRwQCNH/7hq4FQ1x8pjDxYFAESABiDRpgFGHBGAJTW3AhWBBADI6IBHEiAgAnrtRXgrBwxdQ5tmly2DwiY40CBQI/hRzg1Ewzj3i1vGWCOC23BbolsvvLxFg7HaZZOAjgB4qo6RAgEYKo1+JUAOA9SUIAEI9mTGGY0EYDekgxMWYE+LsjlYil/nALvooQE4mhCN45AgMjYCgvNZaHtJ+bkq8zODgnJfFMCDI9INI8lx00jgFQwPupvmkoNm6qnLnoqDpANOXXrYqQ/QF+qCkfn6oozuaLOSZzbhSBqOxs7aYSkSk3wkMhQgABCt12B1SCjpzjkLD/Iu4+bawCgQsF4WCFnkwP97ikmcb1P0unHfHgfpKW1mHWS6eKxSEyw+NncbEqqsOnuKuCmuGBqGzed1pI2EsLXoeBqg3oBBDHBAAQOQeeOBA47xjHGTaXQLd+jjHfF4g+HYY5oFKA5c7/jfTZaUMzuFQnfFex70hga5oXkKEMnIFCAao6+pFaJyfKAAY7CGNinoC1sAkFojMMWVBGxidHJpHwcLNqxnZM19ksjKSDITjgdW4T4YAtXrJMEA5OnOCemAwNwAgsAKqmKJBLFAri7IIcrZDnfBeAax3vCIIZ4kI5ZIAANG0sU0uAhDvQsSX5iIhRUNYowAcACemHiuCeiDND0jSAZ6mMUN6UtyDon/QJvc0DnupCqIDKBAIIGxnpxlCBhBiWMTNgCPTajxDDerDm4GaBoMTImJHCifIFGZymD4gXDEQIAHCMhAvA0jILLsyQTcqAYIME93J7gREzVgPFUOk5i+scxIHtEodFwhOsLQFjCh6IZnXpKaOstlMbGZTYfEbkAbAAUGfuENBGDgcLiJCSfbALNqxpGS2nTnOx0yzVg44BEduCYbWJUAVvASCwvxxsnWycR2wpOgBZ3EgphwgZpIIVVm+kZWSMTLBejDA9GMBEADmrOaGZSjHW0DI/LhJLAc5gARxcIC4EEShwoDoxlNlPM8GlOZliFVkmqlYUo6AVGgFAF1fEMt/1waRwvOlKhF5U5O4eHTSLAxqH3ZqFGhGlWSKnUSEghgU7MwOKlulauCbClWsaBQYXaVrGXdkTzBijKVNWKlZnXrW7uD0LReYKL6CNQZD3BTuO6Vr5sBqT742ZcKFECkJHlkXxGb2N7UlBuuuQVdCUjAc6RDAnlV7GUx+5uMfIsDHsjAVkgCxD2CgqqZNe1pJ1EJ09C1AwlwACRDk0bUzpa2JqlEPgjbCMvWlre9JQtjd+tb4Q6XuMU17nGRm1zlLpe5zXWuNtf3m+hK956Rqu5zyzrd3mh3u9cFDnexm1jwHma85PUudcOb2fKSZb3sPa9v2ptet8Z3KfSt73u7K//fxAaxYLzh7ykP898dCVi/eyWkEMbalANrZjMLTvB+HFzgvb4JMryhMBZxegQM8+fCEoYrwowAW6aAuH29IbEARKyfE6fYw1vdoUVP8uLfyJhHNG6xW80CNN7k+Dc85pGPb2xWIZVWGEP+jZF5hOQgm1UIYOxNk4EDZSBJecllJQDtenPl7Wj5TFyucnZbuN0wixlNAxjzl7caAXQuRc3bafOZ3oxmOc+ZznW2853xnGc975nPffbznwEdaEEPmtCFNnQ2RQCCQy96Px8YAaMh7Z0POEUAkUbtClpQ1kmzrtJCmMIH8GvpmHra01JQ9FZJXWlOF03VooZrqYvBVVj/T2HWN3G1rFtN61yXtdasvjVZU61rXwPHBP0pQauDvepe/3rUyO60s8lyagB8YNKO3g61MyXtaQ/b17AmdaiZ7RAU8KbXy16KteGwazapu9zsVne4ucOizbT7JISgtFN0bBh7p/ve/C6DthMLNahNgQBnboMEVMjRZDdl4QsnshlCAG1vP3sKJSAGCEQAAIBL4QMS97iwJ56pzB4hAbZCpH/aujU0VI6YKeA2qS3eEBFQXNkSf/i9Qx7yEGRcGBE/gwpA/vGaB/20nv6K+BrwqYI/oAF8cICvdmUrjiSdAK+1YyDugCxS3fza/X4ICELgdWGbhN7+fsgBYl4Md4t9/9Wz9bSahvaUPuVBAK+VAwQk0ICpDSB/0tD7VvL3DAQQwGN5eHDQeu2CjXuj7FRYATFE8Gizj13tw2g85THf9sqPHBrPIENiMseHDIIkI3rgnjRKP7DNZb1tb0Nlw4FOdpp3u9VpD0bDZ497PNw+971/ue9DHnvFCmFTs3gKveBONELoYSRNr/TySeKvNcVudoJUgdARg31SbzoYKdA+8FsdAhangee0J/rQ0W9+KYTA9n2t9VP4oIBKjH5Wh4TA/STgo0rbH/+relL97id/BIlLQO0kLo91Hk8YQEDyNq8BM28S2o/bHvAAJRCz3m9oIgCEnqIB5MBQFGCHIMD5GP8KBImFDxKgAUBw/NpFBLjuDSiQ8dZu8mTj5iiwBmMQ3gpK9+StIdgl57BPWdwE/M5P/YhQ93BQm3xwKcYt/YyQGLRhCHXw+36vAo8QCd9tKWzQAG9wArdQ86pQm1IgApkCBbqQCmGQ7agwC2XwCxXL3pIw/c7wDYtQCJnwCtkwsaIQ5LyB+/KwDqdQDu+QtiiwBRPQAb3wENOwDANRsZ7BDczN8spQDQ1xEU0L49aA1MrPMEDA5fxQDheOEo+rErbj+v5QCh8RFAmNS1jQKbjvAVmgBVFRzoDw38KuDU4xFi1t3BZvBLAPF++QFEMOFn1xGIlx0UqAE4sxGZVxGZkzsRmd8RmhMRqlcRqpsRqt8RqxMRu1cRu5sRu98RvBMRzFcRzJsRzN8RzRMR3VcR3xLAgAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the origin and development of megakaryocytes. The pluripotential stem cell produces a progenitor cell committed to megakaryocyte differentiation (Meg-CFC) which undergoes mitosis. The Meg-CFC eventually stops mitosis and enters endomitosis during which neither cytoplasm nor nucleus divides but DNA replication proceeds and gives rise to polyploid immature precursor cells. Upon completion of endomitosis, the immature progenitor cells become large, morphologically identifiable mature megakaryocytes that shed platelets.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David J Kuter, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25550=[""].join("\n");
var outline_f24_60_25550=null;
var title_f24_60_25551="Pediatric sore throat initial approach";
var content_f24_60_25551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Pediatric sore throat: initial approach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 561px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and adenitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_60_25551=[""].join("\n");
var outline_f24_60_25551=null;
